Discover the benefits of HRT combined with integrative medicine as a holistic approach to managing menopause symptoms.

Abstract

Menopause is one of the most complex and misunderstood biological transitions a woman can experience. For decades, the dominant clinical conversation has centered almost exclusively on hormone replacement therapy (HRT) as the primary intervention, often treating the hormonal decline as the sole driver of menopausal symptoms. However, evidence from leading researchers in mitochondrial biology, neurochemistry, metabolic medicine, and functional endocrinology tells a far more nuanced and compelling story.

In this educational post, I, Dr. Alexander Jimenez, draw on the latest peer-reviewed findings and my own clinical observations to take you on a thorough, scientifically grounded journey through the real biological underpinnings of menopause. We will explore why HRT, while valuable, is an incomplete solution when applied in isolation. We will examine the three primary biological disruptions that HRT alone does not address: systemic chronic inflammation and oxidative stress, mitochondrial dysfunction and NAD+ depletion, and localized hypothalamic and peripheral insulin resistance. We will discuss why these three problems cause every major menopausal symptom, from hot flashes and weight gain to brain fog, depression, anxiety, and loss of libido, far more completely than a simple hormonal deficiency model can explain.

We will also examine the fourteen-day rule for HRT titration, a clinically important principle for achieving hormonal steady state without creating unnecessary symptom turbulence. We will cover the essential micronutrient and nutraceutical protocol that supports mitochondrial function, neurotransmitter synthesis, methylation, and mineral balance during this transition. And critically, we will explore how integrative chiropractic care, practiced within a multidisciplinary framework alongside Dr. Maria Guadalupe Cardenas, MD, our Medical Director and Board-Certified Internist with over 40 years of clinical experience, creates a uniquely comprehensive model of care for women navigating perimenopause and menopause.

This post is grounded in modern, evidence-based research and is designed to be accessible to patients, clinicians, and anyone who wants to understand what is truly happening in the menopausal body and what a comprehensive, biologically informed approach to treatment actually looks like.

The Problem With Treating Only Hormones: Why HRT Is Necessary but Not Sufficient

Let me begin with a statement that I want to be very clear about: HRT is not the villain of this story. Estrogen therapy, progesterone, DHEA, and other hormonal interventions are legitimate, evidence-supported, and in many cases profoundly helpful tools. However, the foundational problem with how HRT is typically applied in conventional practice is this: running HRT handles the hormones, not the underlying biology. And because the biology has been disrupted in multiple simultaneous ways, women often continue to feel terrible despite receiving what should theoretically be adequate hormonal support.

This is not a theoretical concern. It is a clinical reality that I encounter regularly at Injury Medical Clinic PA in El Paso, Texas. Women arrive having been on HRT for months or even years, still experiencing hot flashes, still dealing with crushing fatigue, still struggling with depression and anxiety, still gaining weight around the abdomen despite eating carefully and exercising. When this happens, it is not because the HRT is failing. It is because the biological terrain into which the hormones are being delivered is so disrupted that the hormones cannot perform their intended functions properly.

To understand why, we need to examine the three core biological problems that HRT does not address.

The Three Core Biological Problems HRT Does Not Resolve

Problem One: Chronic Inflammation and Oxidative Stress Block Hormonal Action at the Cellular Level

The first and, in many ways, most immediately impactful biological problem is chronic low-grade systemic inflammation, measurable through biomarkers like C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-?), and markers of oxidative stress such as 8-isoprostane, malondialdehyde (MDA), and oxidized low-density lipoprotein (oxLDL).

HRT does not reliably lower CRP or oxidative stress. This is a critical point. What happens at the vascular level when estrogen hits its receptors in an inflamed environment is instructive. Estrogen normally exerts a powerful vasodilatory effect by stimulating endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide (NO), the primary signaling molecule responsible for smooth muscle relaxation in blood vessel walls. When NO is produced, blood vessels dilate. Blood flow improves. The thermoregulatory system can dissipate heat efficiently. Hot flashes, which are fundamentally events of thermoregulatory failure and vascular dysfunction, are reduced.

However, in the presence of elevated inflammatory cytokines and oxidative stress, this entire cascade is disrupted at multiple points:

• Superoxide radicals, which are dramatically elevated in oxidative stress states, react with nitric oxide in a near-diffusion-limited reaction to produce peroxynitrite, a highly reactive nitrogen species that both destroys existing NO and uncouples eNOS, causing it to produce superoxide rather than NO. This is called eNOS uncoupling, and it is a central mechanism in vascular dysfunction.
• NF-?B, the master transcription factor for the inflammatory response, is activated by both the drop in estrogen and by oxidative stress itself. NF-?B activation suppresses eNOS gene expression and promotes the production of endothelin-1, a potent vasoconstrictor that directly opposes the vasodilatory effects of estrogen.
• Inflammatory cytokines like IL-6 and TNF-? impair estrogen receptor sensitivity at the cellular level through a process called receptor desensitization, meaning that even when estrogen is present and binds to its receptor, the downstream signaling cascade is blunted.

The clinical consequence is exactly what I described above: you receive the hormone, and you keep the hot flashes. The estrogen is present. The receptors are present. But inflammation and oxidative stress have turned off the cellular machinery required to translate that hormonal signal into a physiological response. Prescribing more estrogen in this context does not solve the problem. It can actually worsen it by driving more eNOS uncoupling through increased estrogen metabolism and its associated reactive oxygen species burden.

That is why addressing the inflammatory and oxidative stress burden isn’t optional. It is the biological prerequisite for HRT to work as intended. At our clinic, we assess this systematically through comprehensive inflammatory panels and then address it through targeted interventions, which I will detail later in this post.

The Physiological Mechanism of Hot Flashes: A Thermoregulatory Crisis

To fully appreciate why inflammation matters so much, it helps to understand the precise physiology of a hot flash. A hot flash is not simply a wave of warmth. It is a thermoregulatory failure event driven by a pathological narrowing of the thermoneutral zone in the hypothalamus.

Under normal conditions, the hypothalamus maintains core body temperature within a range of approximately 0.4 degrees Celsius on either side of a central set point. Small upward deviations trigger heat dissipation responses: vasodilation, sweating. Small downward deviations trigger heat conservation: vasoconstriction, shivering. This range is the thermoneutral zone.

During the menopausal transition, estrogen withdrawal changes the hypothalamic arcuate nucleus, specifically affecting KNDy neurons (neurons that co-express kisspeptin, neurokinin B, and dynorphin). These neurons centrally regulate the hypothalamic-pituitary-gonadal axis. In estrogen-deficient states, KNDy neurons become hyperactive and release excess neurokinin B, which acts on NK3 receptors in the median preoptic nucleus of the hypothalamus. This NK3 receptor activation triggers a precipitous drop in the thermoregulatory set point, effectively telling the body that it is overheated when it is not.

The body responds to this false alarm with a full thermoregulatory response: sudden peripheral vasodilation (the flush), sweating, and a sensation of intense heat. Core temperature actually drops slightly during a hot flash, even though it feels like extreme heat. This is classic thermoregulatory overshoot.

Now layer in the inflammatory and oxidative stress problem: when systemic inflammation is elevated, the hypothalamic environment becomes further destabilized. Inflammatory cytokines cross the blood-brain barrier through multiple mechanisms, including through the circumventricular organs, which lack a traditional blood-brain barrier, and through active transport mechanisms mediated by cytokine-specific transporters. IL-1?, IL-6, and TNF-? all directly act on the hypothalamus, altering its thermostatic sensitivity and further narrowing the thermoneutral zone. They also promote microglial activation in the hypothalamus, creating localized neuroinflammation that impairs the preoptic area’s precise temperature sensing and signaling.

Oxidative stress compounds this by damaging mitochondria in hypothalamic neurons, reducing ATP output, and impairing the energy-dependent ion pumps neurons need to maintain proper membrane potential and firing thresholds. This brings us directly to the second major biological problem.

Problem Two: Mitochondrial Dysfunction and NAD+ Depletion Are the Root Cause of Most Menopausal Symptoms

The second biological problem is the most foundational, and it is the one the field of functional medicine has done the most work to elucidate over the past decade: mitochondrial dysfunction driven by NAD+ depletion.

Let me take you through the physiology in detail, because this is where the entire picture of menopausal symptomatology begins to cohere in a way that it never does when viewed purely through the lens of hormonal deficiency.

What Mitochondria Actually Do and Why It Matters

A mitochondrion is an organelle present in virtually every cell in the human body, except for mature red blood cells. While mitochondria have multiple functions, their primary role is converting metabolic fuel into adenosine triphosphate (ATP), the universal energy currency of cellular life. This process occurs through a series of elegantly coordinated biochemical reactions: glycolysis in the cytoplasm, the pyruvate dehydrogenase reaction, the citric acid cycle (Krebs cycle), and most critically, oxidative phosphorylation through the electron transport chain (ETC) embedded in the inner mitochondrial membrane.

Oxidative phosphorylation involves five large protein complexes (Complex I through Complex V) that pass electrons down an energy gradient, pumping protons across the inner mitochondrial membrane to create a proton motive force (the mitochondrial membrane potential, ??m). This proton gradient drives ATP synthase (Complex V), which synthesizes ATP from ADP and inorganic phosphate. The efficiency and output of this system are extraordinary: a single cell can contain hundreds to thousands of mitochondria, each producing enormous quantities of ATP every second.

NAD+ (nicotinamide adenine dinucleotide) is the critical electron carrier that makes oxidative phosphorylation possible. In the Krebs cycle, NAD+ accepts electrons from metabolic intermediates to become NADH. NADH then donates these electrons to Complex I of the electron transport chain, initiating the electron flow that ultimately drives ATP synthesis. Without sufficient NAD+, the electron transport chain cannot function, the Krebs cycle stalls, and ATP production collapses.

The NAD+ Crisis of Menopause: 2021 Nature Cell Biology Findings

A landmark 2021 study published in Nature Cell Biology provided compelling evidence that NAD+ levels decline catastrophically and specifically during the menopausal transition, beyond the normal age-related decline that affects all humans. This finding is enormously significant because it means that menopausal women are facing a compound energy crisis: the normal age-related mitochondrial decline is accelerated by the hormonal transition in a way that creates a qualitatively different physiological state.

The mechanisms underlying this menopausal NAD+ collapse are multiple and interconnected:

• Estrogen directly regulates NAD+ biosynthesis. Estrogen receptor signaling promotes the expression of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of NAD+ synthesis, which is the primary route of NAD+ production in most mammalian cells. When estrogen falls, NAMPT expression decreases, impairing NAD+ biosynthesis at its most critical regulatory step.
• CD38, an enzyme that consumes NAD+ in a catabolic process, becomes increasingly active with age and during inflammatory states. Elevated inflammatory cytokines during the menopausal transition upregulate CD38 activity, accelerating NAD+ consumption and further depleting the cellular pool.
• PARP (poly ADP-ribose polymerase) enzymes, activated by oxidative DNA damage, also consume large amounts of NAD+. Oxidative stress during menopause activates PARPs, creating a vicious cycle: oxidative stress depletes NAD+, NAD+ depletion worsens mitochondrial function, impaired mitochondria produce more reactive oxygen species, which cause more oxidative stress and further PARP activation.
• SIRT1 and SIRT3, the sirtuins that depend on NAD+ as a cofactor and that regulate mitochondrial biogenesis, antioxidant defense, and cellular stress responses, lose their activity when NAD+ falls. This impairs the cell’s capacity to repair mitochondrial damage, synthesize new mitochondria (a process called mitophagy and mitochondrial biogenesis), and mount effective antioxidant defenses.

The result is a self-amplifying downward spiral: estrogen falls, NAD+ falls, mitochondrial function deteriorates, oxidative stress rises, inflammation rises, CD38 and PARP activation increases, NAD+ falls further, and mitochondrial function deteriorates more. This cycle, if not interrupted by targeted intervention, drives every major symptom of menopause.

Hot Flashes as a Mitochondrial Event

As I described in the thermoregulatory section above, hypothalamic neurons require ATP to maintain their membrane potential, regulate ion channel function, and precisely calibrate thermostatic signals. When mitochondrial function fails in these neurons, their capacity to maintain precise thermoregulatory control is compromised. The thermoneutral zone narrows. The system becomes hyper-reactive. The result is hot flashes driven by energy-starved hypothalamic neurons that cannot perform their regulatory functions.

This explains why women with the worst hot flashes often have the highest markers of oxidative stress and the greatest mitochondrial dysfunction. The hormone is part of the story, but the cellular energy crisis amplifies manageable hormonal fluctuations into debilitating thermoregulatory events.

Brain Fog as a Mitochondrial and Neuroenergetic Event

Brain fog is one of the most universally reported and least well-understood menopausal symptoms. Women describe it as a loss of mental sharpness, difficulty with word retrieval, impaired concentration, and a subjective sense of cognitive cloudiness that can be profoundly distressing, particularly for high-functioning women who have never before experienced cognitive limitations.

The neuroenergetic explanation is compelling. The brain is the most metabolically demanding organ in the human body, consuming approximately 20% of total body energy despite representing only about 2% of body weight. The cerebral cortex, and particularly the prefrontal cortex, which handles executive function, working memory, decision-making, and complex cognitive processing, has an extraordinarily high ATP requirement. Mitochondrial oxidative phosphorylation meets this demand almost entirely; neurons have very limited glycolytic capacity compared to other cell types and cannot sustain function on anaerobic metabolism.

When NAD+ falls and mitochondrial function deteriorates, cortical neurons become energy-starved. Their capacity to maintain the ion gradients required for action potential generation and synaptic transmission is compromised. Neural computation slows and becomes less efficient. Working memory capacity decreases. Word retrieval slows. This cognitive experience is exactly what women describe as brain fog.

Furthermore, synaptic plasticity, the cellular basis of learning and memory, requires enormous amounts of ATP for processes like long-term potentiation (LTP), AMPA receptor trafficking, and dendritic spine remodeling. Energy-starved neurons have impaired synaptic plasticity, which contributes to the memory difficulties that many menopausal women report.

Depression, Anxiety, and Irritability: The Neuroenergetic Model of Mood Disruption

This is a point that I feel particularly strongly about, and I want to address it directly and without hedging: the framing of menopausal depression, anxiety, and irritability as simply “hormonal” is not only scientifically incomplete; it is dismissive and harmful.

Women in perimenopause and menopause are not emotionally unstable because they are hormonal. They are neurochemically destabilized because their neurons lack the ATP to synthesize, release, and recycle neurotransmitters. This is a metabolic problem, not a character or emotional problem.

Let me walk you through the neuroscience. The prefrontal cortex (PFC) is the brain region most responsible for emotional regulation, impulse control, rational decision-making, and suppressing limbic system reactivity. The PFC exerts top-down inhibitory control over the amygdala, the brain’s threat-detection and emotional reactivity center. When the PFC functions well, it can modulate amygdala responses to stressors, preventing emotional overreactivity and supporting calm, rational responses to challenges.

This PFC-amygdala regulatory relationship is critically dependent on ATP. The PFC has a very high energy demand, and its inhibitory control over the amygdala is one of the first functions to fail when cortical neurons become energy-starved. When the PFC loses its capacity to suppress amygdala reactivity, women experience emotional lability, irritability, anxiety, and a sense of emotional dysregulation that is frightening and alien to their normal experience of themselves.

Simultaneously, the synthesis of the major mood-regulating neurotransmitters is an ATP-dependent process:

• Serotonin synthesis requires the conversion of tryptophan to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase, and then the decarboxylation of 5-HTP to serotonin by aromatic L-amino acid decarboxylase (AADC). Both enzymes require cofactors (particularly pyridoxal-5-phosphate, the active form of vitamin B6) whose regeneration and activity are ATP-dependent. The axonal transport of tryptophan into the neuron is also an active, energy-dependent process.
• Dopamine synthesis follows the same pathway: tyrosine hydroxylase converts tyrosine to L-DOPA, and AADC converts L-DOPA to dopamine. Both steps require adequate neuronal energy.
• GABA synthesis from glutamate by glutamic acid decarboxylase (GAD) is also energy-dependent, as is the packaging of GABA into synaptic vesicles by the vesicular GABA transporter (VGAT).
• The reuptake of neurotransmitters after synaptic release, which terminates their signaling and recycles them for reuse, is performed by sodium-dependent reuptake transporters (SERT for serotonin, DAT for dopamine, NET for norepinephrine, GAT for GABA), all of which require the sodium gradient maintained by the Na+/K+ ATPase pump, one of the most ATP-hungry proteins in the neuron.

This is the fundamental reason why antidepressants often fail menopausal women: you cannot treat low serotonin by blocking its reuptake if the neurons have no energy to synthesize serotonin in the first place. SSRIs assume that there is adequate serotonin being produced but not staying in the synapse long enough. In the menopausal brain, the problem is often upstream: the neuron is too energy-depleted to synthesize sufficient serotonin, regardless of whether its reuptake is inhibited. The tank is empty. Blocking the drain does not fill the tank.

This does not mean antidepressants have no role. But it does mean that treating menopausal mood disorders without addressing the underlying mitochondrial energy crisis is likely to be at best partially effective and at worst a complete failure. The appropriate clinical response is to restore cellular energy production first, and then reassess whether pharmacological neurotransmitter support is still necessary.

Problem Three: Localized Insulin Resistance in the Hypothalamus and Metabolic Tissues Creates a Metabolic Paralysis State

The third biological problem is among the most clinically consequential and least discussed: localized insulin resistance that develops specifically in the hypothalamus and metabolic tissues (skeletal muscle, adipose tissue, liver) during the menopausal transition.

Understanding this requires first understanding the normal role of insulin signaling in the brain and in peripheral metabolic tissues.

Insulin Signaling in the Brain: More Than Just Glucose Regulation

The traditional view of insulin as a purely peripheral metabolic hormone is outdated. The brain, and specifically the hypothalamus, has abundant insulin receptors that play critical roles in:

• Regulating energy homeostasis and food intake through modulation of neuropeptide Y (NPY) and pro-opiomelanocortin (POMC) neurons in the arcuate nucleus.
• Controlling peripheral metabolic function through autonomic nervous system outputs to the liver, adipose tissue, and skeletal muscle.
• Supporting mitochondrial function in hypothalamic neurons through insulin-stimulated signaling pathways that promote mitochondrial biogenesis and reduce mitochondrial oxidative stress.
• Modulating the thermoregulatory response through insulin receptor signaling in the preoptic area and arcuate nucleus, which directly affects the KNDy neuron activity discussed above.

When hypothalamic insulin resistance develops, all of these functions are impaired. The hypothalamus loses its ability to accurately sense and respond to peripheral metabolic signals, creating metabolic discoordination in which the brain and body no longer communicate efficiently about energy status.

The Estrogenic Regulation of Insulin Sensitivity: Why Menopause Breaks Metabolic Signaling

Estrogen profoundly regulates insulin sensitivity. Estrogen receptor alpha (ER?), which is expressed in both hypothalamic neurons and peripheral metabolic tissues, promotes insulin sensitivity through multiple mechanisms:

• ER? signaling upregulates GLUT4 transporter expression and membrane translocation in skeletal muscle and adipose tissue, increasing insulin-stimulated glucose uptake.
• ER? activates PI3K-Akt signaling, the primary intracellular pathway through which insulin exerts its metabolic effects, in hypothalamic neurons.
• Estrogen suppresses the expression of protein tyrosine phosphatase 1B (PTP1B), an enzyme that inactivates the insulin receptor and the insulin receptor substrate proteins, thereby maintaining insulin receptor sensitivity.
• Estrogen promotes adiponectin secretion from adipose tissue, and adiponectin is a key insulin-sensitizing adipokine that also activates the AMPK pathway to promote mitochondrial biogenesis.

When estrogen falls during menopause, all of these insulin-sensitizing mechanisms are withdrawn simultaneously. The result is a rapid development of both central (hypothalamic) and peripheral insulin resistance, creating a metabolic environment in which the mitochondria are, as I described above, soaked in glucose but unable to use it efficiently.

Why Mitochondria Cannot Process Glucose in the Insulin-Resistant State

Here is the specific mitochondrial problem insulin resistance creates. When insulin signaling is impaired, cells struggle to take up glucose despite elevated circulating glucose levels. The compensatory hyperinsulinemia that typically follows creates its own problems, but the cellular energy problem is this: mitochondria face a disordered fuel supply.

In the insulin-resistant state:

• Glucose entry into cells is impaired, so mitochondria in muscle and brain cells cannot access their primary fuel efficiently.
• Fatty acid oxidation is impaired because elevated insulin levels (even in a relative insulin-resistant state, circulating insulin is often elevated due to compensatory pancreatic output) suppress hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) in fat cells, preventing the mobilization of stored fatty acids for beta-oxidation.
• The combination of impaired glucose utilization and impaired fatty acid mobilization means that mitochondria are fuel-deprived despite the body being in caloric surplus. Cells cannot access what they need to make ATP.
• Meanwhile, glucose that cannot be metabolized is preferentially directed toward de novo lipogenesis in the liver and adipose tissue, producing visceral fat accumulation through VLDL synthesis and triglyceride storage.
• The hypothalamus, sensing cellular energy deprivation despite sufficient fuel in circulation, initiates hunger signals through elevated NPY and reduced POMC activity, driving increased food intake that further exacerbates the cycle.

This is the precise biological mechanism behind the menopausal weight gain that so many women struggle with and feel so blamed for. It is not a caloric problem. It is not a failure of willpower or discipline. It is a fundamental metabolic reorganization driven by estrogen withdrawal, hypothalamic insulin resistance, and mitochondrial energy failure. Calories-in-calories-out thinking is not only unhelpful in this context; it is biologically incorrect and psychologically damaging to women who are working hard to manage their weight and being told they simply are not trying hard enough.

The visceral fat that accumulates during this metabolic transition is not metabolically inert. Visceral adipose tissue (VAT) is highly inflammatory. It secretes elevated levels of IL-6, TNF-?, and resistin, all of which worsen insulin resistance, increase CRP, and drive further oxidative stress. VAT also produces excess aromatase, which converts androgens to estrogens locally, creating a disordered estrogen-signaling environment. This creates yet another vicious cycle: metabolic disruption causes visceral fat accumulation, which worsens inflammation, which worsens insulin resistance, which causes more visceral fat accumulation.

NAD+ Decline, Mitochondrial Collapse, and the Menopausal Symptom Constellation: Connecting the Dots

Now that we have established the three primary biological problems, I’ll show how they converge to produce the complete menopausal symptom constellation. This synthesis is important because it reframes menopause not as a simple hormonal deficiency but as a multisystem energy and signaling crisis.

Hot Flashes: The Convergence of All Three Problems

• Problem 1 contribution: Inflammation and oxidative stress impair eNOS function and nitric oxide availability, preventing adequate peripheral vasodilation to dissipate heat. They also directly destabilize hypothalamic thermoregulatory neurons through neuroinflammatory mechanisms.
• Problem 2 contribution: NAD+ depletion and mitochondrial dysfunction in hypothalamic neurons impair the precise ATP-dependent thermostatic control mechanisms. KNDy neurons become hyperactive and misfire thermoregulatory responses.
• Problem 3 contribution: Hypothalamic insulin resistance disrupts the complex interplay between metabolic sensing and thermoregulatory control in the arcuate nucleus and preoptic area.

The convergence of all three problems in the hypothalamus creates a thermoregulatory system that is simultaneously inflamed, energy-starved, and metabolically confused. The result is the hot flash: a false alarm triggered by a system that has lost its precision.

Fatigue: The Direct Consequence of Cellular ATP Insufficiency

Fatigue in menopause is almost universally explained away as “just getting older” or “stress,” but the biology is specific and addressable. When NAD+ falls and mitochondrial function deteriorates across the body, ATP output falls systemically. Every cell, every tissue, every organ becomes less efficient at producing the energy it needs to function.

• Skeletal muscle cells have reduced oxidative phosphorylation capacity, so physical activity relies disproportionately on glycolysis, producing lactate and causing rapid muscular fatigue.
• Cardiac myocytes, among the body’s highest-energy-demand cells and almost exclusively dependent on mitochondrial ATP production, function less efficiently, reducing cardiac reserve and contributing to exercise intolerance.
• Immune cells have impaired function, requiring more energy to mount immune responses, which diverts energy from other systems.
• Neuronal cells have reduced ATP for all of the functions described above, including neurotransmitter synthesis, synaptic transmission, and axonal transport.

The subjective experience of systemic ATP insufficiency is profound, disabling fatigue that sleep does not relieve (because mitochondrial dysfunction also impairs the ATP-dependent processes of sleep architecture maintenance and memory consolidation during sleep) and that is not durably responsive to caffeine or other stimulants.

Weight Gain: The Metabolic Trap

As detailed above, the combination of:

• Peripheral insulin resistance preventing normal glucose disposal into muscle
• Hypothalamic insulin resistance driving increased appetite signaling
• Impaired lipolysis preventing fat mobilization for energy
• Compensatory hyperinsulinemia promoting lipogenesis and fat storage
• Mitochondrial inefficiency reducing resting metabolic rate

…creates a metabolic trap in which the body is simultaneously storing fat it cannot access and failing to use the metabolic fuel it needs. The clinical response of prescribing caloric restriction and increased exercise, while not without merit, addresses none of the upstream biological drivers and frequently fails to produce sustained benefit.

Loss of Libido: The Neuroenergetic and Hormonal Convergence

Loss of libido (hypoactive sexual desire disorder, HSDD) in menopause has multiple drivers, but the mitochondrial and neuroenergetic contributions are underappreciated. Sexual desire is a complex neurological phenomenon that involves:

• Dopaminergic reward signaling in the mesolimbic system (the nucleus accumbens and ventral tegmental area), which requires adequate ATP for dopamine synthesis, vesicular packaging, and release.
• Testosterone and DHEA signaling in the brain through androgen receptors in the amygdala, hypothalamus, and prefrontal cortex, which modulate sexual motivation and responsiveness.
• Nitric oxide-dependent genital engorgement through vasodilation, which requires functional eNOS signaling.
• Adequate vaginal tissue health (the integrity of which depends on both estrogen and localized mitochondrial function in epithelial cells).

When mitochondrial function is impaired, dopaminergic reward signaling is blunted (contributing to anhedonia in addition to reduced libido), nitric oxide-dependent vasodilation is impaired (both through eNOS uncoupling in the context of oxidative stress and through reduced ATP availability for eNOS activity), and vaginal tissue integrity is further compromised by the same energy deficit that affects all epithelial tissues.

The Fourteen-Day Rule: Why HRT Titration Requires Patience and Precision

Now that we have established the biological context, let me discuss the clinical management framework, beginning with what I call the fourteen-day rule.

Understanding Hormonal Steady State: Why Time Matters in HRT Dosing

When you start a new HRT regimen or adjust a dose, the hormones do not immediately achieve stable blood levels. Pharmacokinetically, most hormone preparations require approximately 14 days to reach tissue steady state. This fundamental pharmacokinetic principle is based on half-life and tissue distribution equilibrium.

For transdermal estradiol, which is absorbed through the skin and distributed primarily to tissues rather than achieving high peak plasma levels (as oral estradiol does), the process of equilibrating in tissues involves:

• Absorption through the stratum corneum and underlying dermis into the systemic circulation.
• Binding to sex hormone-binding globulin (SHBG) in the blood, creating a circulating reservoir of bound hormone that is in dynamic equilibrium with the free fraction.
• Uptake into target tissues, where estradiol binds to estrogen receptors in the nucleus and initiates changes in gene expression.
• Genomic responses to estrogen receptor activation, which involve transcription and translation of estrogen-responsive genes, take hours to days to manifest, and the cumulative tissue-level response to new gene expression takes multiple rounds of transcription-translation to build up to its full effect.

This means that the subjective and objective response to a new estradiol dose is not instantaneous. A woman starting transdermal estradiol will not experience the full effect of that dose until approximately two weeks have passed, when both pharmacokinetic steady state and the downstream genomic responses have had time to develop.

The Clinical Catastrophe of Over-Titration: Why Frequent Dose Adjustments Create Chaos

The most common clinical mistake I see in HRT management is dose adjustment every three days or less, typically done in response to continuing or new symptoms that the prescriber interprets as evidence of underdosing or overdosing. This approach is well-intentioned but creates significant problems.

When you adjust a hormone dose before the previous dose has reached steady state, you add a new perturbation to a system still trying to equilibrate. The result is pharmacological turbulence: superimposed concentration fluctuations that create symptom patterns that are harder to interpret and often worse than the original problem.

Specifically, frequent estrogen dose adjustments can create more hot flashes than were present at baseline, through a mechanism involving the sensitization of estrogen receptor populations. When estrogen levels fluctuate rapidly due to frequent dosing changes, estrogen receptors in the hypothalamus undergo desensitization and resensitization cycles that increase the thermoregulatory system’s responsiveness to hormonal fluctuations. The hypothalamus becomes hypersensitive to hormonal changes, and even normal pharmacokinetic variations in transdermal estradiol absorption (which vary with skin hydration, body temperature, and application site) can trigger hot flashes.

The clinical discipline of waiting fourteen days before assessing a dose change is not passive; it is essential to rational HRT management. I emphasize this to every patient at Injury Medical Clinic PA: you must give the hormone time to do its job before deciding it is not working.

The Optimal HRT Protocol: Evidence-Based Specifics

Based on current evidence and my clinical experience, the foundational HRT protocol for menopausal women involves:

Transdermal Estradiol

• Applied once daily, ideally to thin skin areas (inner wrist, inner upper arm, inner thigh) to ensure consistent absorption.
• Transdermal delivery is preferred over oral for several reasons: it avoids first-pass hepatic metabolism, which reduces conversion of estradiol to estrone (a weaker estrogen), and it avoids the procoagulant and inflammatory effects of oral estrogen on the liver, including elevation of CRP, clotting factors, and triglycerides.
• Monitor estradiol levels at 6 weeks after initiation. Target range is typically 30-100 pg/mL for symptom control, though individual response varies. Levels consistently above 100 pg/mL suggest the dose is too high and should be reduced.

Oral Micronized Progesterone

• Taken at bedtime only. This timing is not arbitrary. Progesterone has GABA-A receptor modulatory effects through its neurosteroid metabolite allopregnanolone, producing sedative and anxiolytic effects that support sleep quality. Taking progesterone at bedtime leverages this mechanism beneficially while avoiding the daytime sedation that can occur if it is taken in the morning.
• Micronized progesterone (Prometrium) is preferred over synthetic progestins (medroxyprogesterone acetate, norethindrone) because it has a more physiological receptor binding profile, does not antagonize many of the cardiovascular benefits of estrogen, and does not produce the negative mood effects associated with some synthetic progestins.

DHEA (Dehydroepiandrosterone)

• Taken in the morning, which aligns with the natural diurnal pattern of adrenal DHEA secretion (highest in the morning, declining through the day).
• DHEA serves as a precursor to both androgens and estrogens and supports libido, energy, cognitive function, and immune regulation.
• If a woman experiences irritability, oily skin, acne, or unwanted hair growth, these are signs of excessive androgenic conversion, and the appropriate response is to cut the DHEA dose in half rather than discontinuing it entirely. These symptoms reflect excessive conversion of DHEA to testosterone or dihydrotestosterone, and a lower dose typically resolves them while maintaining benefit.

Managing Common HRT Side Effects: A Systematic Approach

Chest Tenderness (Mastalgia)

Breast tenderness after starting or increasing estrogen is a common and typically benign side effect driven by estrogen-stimulated breast tissue proliferation and fluid retention. The appropriate clinical response:

1. Lower the estrogen dose first. If a dose reduction resolves the tenderness within 2 weeks, the original dose was too high for that individual.
2. Check B6 and methylation status. Vitamin B6 (pyridoxine) and methylation capacity (assessed through homocysteine levels, MTHFR genotyping, and methylmalonic acid) affect estrogen metabolism. Poor methylation can lead to accumulation of estrogen metabolites, particularly the more proliferative and potentially genotoxic 4-hydroxyestrone and 16-alpha-hydroxyestrone, relative to the more benign 2-hydroxyestrogens. Supporting methylation with methylated B vitamins (methylfolate, methylcobalamin, pyridoxal-5-phosphate) improves estrogen metabolism and reduces the tissue burden of problematic metabolites.

Jitteriness, Anxiety, and Palpitations

If a woman reports feeling “wired,” anxious, or jittery after starting or adjusting HRT, the most common causes are:

1. Excessive DHEA dose leading to elevated androgens and overstimulation of the adrenergic system.
2. Insufficient magnesium and taurine to buffer the neurological and cardiovascular effects of hormonal shifts. This is an extremely common problem because both magnesium and taurine are chronically depleted in modern diets and are consumed at accelerated rates during periods of physiological stress and metabolic change.

Magnesium is a cofactor for over 300 enzyme reactions. It is essential for regulating NMDA (N-methyl-D-aspartate) glutamate receptors, the brain’s primary excitatory receptors. When magnesium is deficient, NMDA receptors become hypersensitive to glutamate, causing neurological hyperexcitability that manifests as anxiety, jitteriness, muscle cramps, sleep disturbance, and palpitations. Taurine is a conditionally essential amino acid that directly stabilizes membranes, modulates GABA receptor sensitivity, supports cardiac rhythm stability, and reduces neurological excitability.

Aligned & Empowered: Chiropractic Conversations on Women’s Health-Video

The Essential Micronutrient and Nutraceutical Protocol: The Non-Negotiable Biological Foundations

Perhaps the most important message I want to convey in this educational post is this: a set of micronutrients and nutraceuticals is not optional for menopausal women. They are the raw biological materials the body needs to function. No amount of HRT precision, dietary optimization, or lifestyle modification can compensate for the absence of these foundational molecular building blocks.

Let me go through each one in detail, explaining the physiological reasoning for why it is essential.

Magnesium: The Master Mineral for Neurological and Metabolic Function

Magnesium is the fourth most abundant mineral in the human body and arguably the most important for menopausal women. Its deficiency is extraordinarily common: estimates suggest that up to 50-80% of the U.S. population does not consume adequate magnesium from dietary sources, and menopausal women have additional risk factors for deficiency:

• Estrogen normally promotes renal magnesium reabsorption; when estrogen falls, renal magnesium wasting increases.
• Elevated cortisol (from HPA axis dysregulation common in menopause) increases urinary magnesium excretion.
• Gut dysbiosis (also common during the hormonal transition) impairs magnesium absorption.

Physiological roles relevant to menopause:

• NMDA receptor modulation: As described above, magnesium blocks NMDA receptors at rest, preventing excessive glutamate excitotoxicity. This is critical for managing anxiety, mood stability, and sleep.
• Mitochondrial function: Magnesium is required to activate all ATP-dependent enzymes. ATP in the cell almost always exists as a Mg2+-ATP complex. Without adequate magnesium, ATP cannot be utilized efficiently, even if it is being produced. Mitochondrial Complex I, II, and V all require magnesium for optimal function.
• Insulin signaling: Magnesium is required for the activity of tyrosine kinase, the enzyme that initiates insulin receptor signaling. Magnesium deficiency directly causes insulin resistance.
• Thermoregulation: Magnesium participates in hypothalamic temperature regulation by influencing neuronal membrane potential and neurotransmitter release.
• Bone metabolism: Magnesium is required for the activation of vitamin D (through its role in 25-hydroxylase and 1-alpha-hydroxylase enzyme function) and for the function of parathyroid hormone (PTH). Without adequate magnesium, vitamin D supplementation is ineffective, and bone metabolism is impaired.

Clinical forms: Magnesium glycinate or magnesium threonate are preferred for neurological and cognitive applications because of their superior bioavailability and CNS penetration. Magnesium oxide has very poor bioavailability and is not recommended. Typical therapeutic doses for menopausal women range from 300-500 mg elemental magnesium daily.

Potassium: Vascular Function and Cellular Membrane Potential

Potassium is the primary intracellular cation and is essential for maintaining the resting membrane potential of all cells, particularly neurons and cardiac myocytes. The Na+/K+ ATPase pump that maintains the steep sodium-potassium gradient across the cell membrane consumes approximately 20-40% of total neuronal ATP.

In the context of menopause:

• Potassium deficiency impairs neuronal firing thresholds, contributing to anxiety and mood instability.
• Adequate potassium intake is associated with reduced blood pressure, which is clinically important given the cardiovascular risk increase that accompanies menopause.
• Potassium supports renal calcium conservation, which is important for bone health.
• Potassium helps regulate cardiac rhythm, and potassium-magnesium co-depletion commonly causes palpitations and cardiac ectopy in menopausal women.

Vitamin D3 with Vitamin K2: The Bone, Immune, and Metabolic Foundation

Vitamin D3 (cholecalciferol) is not simply a vitamin; it is a prohormone that, after sequential hydroxylation in the liver and kidney, becomes 1,25-dihydroxycholecalciferol (calcitriol), the active hormone that binds to vitamin D receptors (VDR) expressed in virtually every tissue in the body.

In menopausal women, vitamin D has critical roles in:

• Bone metabolism: Vitamin D promotes intestinal calcium absorption and renal calcium retention. Together with estrogen, it is the primary determinant of bone mineral density maintenance. Without adequate vitamin D, even estrogen-replete women lose bone mass.
• Immune regulation: VDR signaling in immune cells promotes anti-inflammatory Treg cell activity and reduces Th17-mediated inflammatory signaling. Given the inflammatory burden of menopause, adequate vitamin D has direct anti-inflammatory effects.
• Insulin sensitivity: VDR signaling in pancreatic beta cells promotes insulin secretion, and in skeletal muscle promotes GLUT4 expression. Vitamin D deficiency contributes to insulin resistance.
• Mood regulation: VDR is expressed in the substantia nigra, hypothalamus, and prefrontal cortex. Calcitriol regulates the expression of tyrosine hydroxylase (the rate-limiting enzyme for dopamine synthesis) and tryptophan hydroxylase (for serotonin synthesis). Vitamin D deficiency is consistently associated with depression, and supplementation has mood-improving effects in deficient individuals.
• Muscle function: VDR in skeletal muscle regulates muscle protein synthesis, mitochondrial function, and calcium handling. Vitamin D deficiency contributes to the muscle weakness and reduced exercise capacity many menopausal women experience.

Vitamin K2 (menaquinone-7, MK-7) must be administered alongside vitamin D3 in any serious supplementation protocol, and here is why: vitamin D increases the production of osteocalcin and matrix Gla protein (MGP). These two proteins direct calcium into bones and prevent its deposition in soft tissues (blood vessels, kidneys). However, these proteins are only activated through a carboxylation reaction that requires vitamin K2. Without K2, vitamin D-mobilized calcium can deposit in arterial walls rather than bone, potentially worsening cardiovascular risk. Vitamin K2 ensures that calcium goes where it belongs.

Boron: The Overlooked Mineral for Hormonal and Bone Health

Boron is a trace mineral that receives little attention in clinical practice, despite its important and well-documented effects on hormone metabolism and bone health. In the context of menopausal women:

• Boron inhibits SHBG (sex hormone-binding globulin) activity, effectively increasing the free (bioavailable) fraction of both estrogen and testosterone. This means that adequate boron intake can support hormonal bioavailability independently of total hormone levels.
• Boron supports enzymes involved in estrogen and testosterone synthesis in the adrenal cortex and peripheral tissues.
• Boron is required for parathyroid hormone function and 1-alpha-hydroxylase, the enzyme that activates vitamin D in the kidney. Boron deficiency impairs vitamin D activation and contributes to bone loss.
• Boron has direct anti-inflammatory effects, reducing circulating inflammatory markers including CRP and TNF-?.

Typical therapeutic doses are 3-6 mg daily, and it occurs in small amounts in fruits, vegetables, and nuts, though modern diets rarely provide adequate intake.

Zinc: Immune Function, Hormonal Regulation, and Neurological Health

Zinc is an essential trace mineral that functions as a cofactor for over 300 enzymatic reactions and as a structural component of over 2,000 transcription factors. Its relevance to menopausal women is broad:

• Hormonal function: Zinc is required for the proper folding and function of the estrogen receptor ligand-binding domain and the androgen receptor. Without adequate zinc, hormone receptors cannot bind their ligands efficiently, meaning that hormonal signaling is impaired even when hormone levels are adequate.
• Immune regulation: Zinc is the most critical nutrient for immune function. T cell development, NK cell activity, and neutrophil function all depend on zinc. The increased infection susceptibility many menopausal women notice reflects, in part, zinc depletion.
• Thyroid function: Zinc is required to convert T4 to the active T3 form of thyroid hormone. Thyroid dysfunction (particularly hypothyroidism) is common in menopausal women and is often exacerbated by zinc deficiency.
• Testosterone synthesis: Zinc is essential for testosterone biosynthesis and is depleted by sweating. Women who experience heavy night sweats may be particularly at risk for zinc depletion.
• Neurological function: Zinc modulates NMDA and GABA receptor function, influences serotonin transporter activity, and is concentrated in synaptic vesicles in the hippocampus and prefrontal cortex, where it modulates synaptic signaling.

Taurine: The Neurological Buffer and Cardiovascular Protector

Taurine is a conditionally essential amino acid (sulfonic acid) that is the most abundant free amino acid in the brain and heart. Its roles in the menopausal context are multiple and powerful:

• GABA receptor modulation: Taurine directly activates GABA-A receptors, producing anxiolytic, anticonvulsant, and sleep-promoting effects. In the context of menopausal anxiety and sleep disruption, taurine supplementation can be profoundly helpful.
• Mitochondrial protection: Taurine is incorporated into mitochondrial tRNA as a modified nucleotide (5-taurinomethyluridine) and is essential for proper translation of mitochondrially encoded Complex I, III, IV, and V subunits. Taurine deficiency causes mitochondrial tRNA mistranslation and impaired ETC function. This is a direct mechanism by which taurine supports mitochondrial ATP production.
• Antioxidant defense: Taurine reacts with hypochlorous acid (produced by activated neutrophils during inflammation) to form taurine chloramine, a less reactive oxidant that reduces oxidative tissue damage. It also directly scavenges reactive oxygen species.
• Cardiovascular function: Taurine supports cardiac contractility by regulating calcium handling in cardiomyocytes, maintains endothelial function, and has direct antihypertensive effects through autonomic modulation and natriuresis.
• Bile acid conjugation: Taurine conjugates bile acids in the liver, supporting fat-soluble vitamin absorption and reducing hepatic inflammation. Because estrogen metabolism is a hepatic process, liver support is directly relevant to HRT optimization.

Methylated B Vitamins: The Engine of Estrogen Metabolism and Neurotransmitter Synthesis

Methylated B vitamins (specifically methylfolate (5-MTHF), methylcobalamin (active B12), and pyridoxal-5-phosphate (P5P, active B6)) are among the most critical micronutrients for menopausal women, yet their importance is often underestimated in conventional practice.

Their primary relevance is through methylation, the biochemical process of adding a methyl group (CH3) to substrates. Methylation is one of the most fundamental and pervasive biochemical processes in the human body, affecting:

• DNA methylation: Epigenetic regulation of gene expression, including the expression of inflammatory genes, tumor suppressor genes, and genes involved in neurotransmitter synthesis.
• Neurotransmitter synthesis and degradation: SAM (S-adenosylmethionine), the universal methyl donor, is required for the synthesis of norepinephrine from dopamine (by PNMT), the catabolism of catecholamines by COMT, and the regulation of multiple neurotransmitter synthesis pathways.
• Estrogen metabolism: The conversion of estrogens to 2-methoxyestrone and 2-methoxyestradiol (benign, antiproliferative metabolites) requires COMT. Women with poor methylation capacity accumulate more proliferative 4-OH and 16-OH estrogen metabolites, which are associated with increased breast tissue stimulation and potentially carcinogenic DNA adduct formation.
• Homocysteine remethylation: Homocysteine is a toxic amino acid that damages blood vessel walls, impairs nitric oxide production, promotes thrombosis, and causes neurological damage. Its remethylation back to methionine requires MTHFR (methylenetetrahydrofolate reductase) and active folate and B12. Elevated homocysteine is extraordinarily common in menopausal women and is an independent risk factor for cardiovascular disease, stroke, dementia, and osteoporosis.

Up to 30-40% of individuals carry MTHFR polymorphisms (C677T or A1298C) that reduce MTHFR activity by 30-70%, impairing their ability to convert dietary folate and folic acid into the active methylfolate form. For these individuals, supplementation with methylfolate (not folic acid) is essential for maintaining adequate methylation capacity.

Why Lab Testing Is Essential: The “Get Labs Today” Principle

Do not apply any micronutrient protocol without laboratory guidance. My standard approach is to obtain a comprehensive baseline panel before starting any hormonal or nutraceutical protocol, and then repeat it approximately six weeks after initiation to assess response. This allows for precise, individualized titration rather than generic dosing.

Key laboratory assessments include:

• Comprehensive hormonal panel: Estradiol, FSH, LH, progesterone, total and free testosterone, DHEA-S, SHBG, cortisol (ideally a 4-point salivary cortisol), thyroid panel (TSH, free T3, free T4, reverse T3, thyroid antibodies).
• Metabolic panel: Fasting glucose, fasting insulin, HbA1c, HOMA-IR calculation, comprehensive metabolic panel (liver and kidney function, electrolytes).
• Inflammatory markers: hsCRP, IL-6, homocysteine, fibrinogen.
• Nutritional status: 25-OH vitamin D, RBC magnesium (not serum magnesium, which is a poor indicator of cellular magnesium status), RBC zinc, whole blood selenium, ferritin and full iron panel, B12, methylmalonic acid.
• Lipid panel with particle sizing: LDL particle number, LDL particle size, HDL2b, oxidized LDL.
• Bone markers: If indicated, bone turnover markers (osteocalcin, CTX) and DEXA scan.
• Organic acids: A comprehensive organic acids test can provide direct evidence of mitochondrial dysfunction (elevated succinate, fumarate, malate suggesting Krebs cycle impairment; elevated lactate/pyruvate ratio suggesting ETC dysfunction), B vitamin status, and oxidative stress.

Testing and then adjusting based on results is not just good medicine. It is the difference between guessing and knowing. At Injury Medical Clinic PA, we believe that every woman deserves the precision of data-guided care, not just standard protocols.

Integrative Chiropractic Care in Menopausal Health: The Neurological and Structural Dimension

I now want to turn to a dimension of menopausal health management that is rarely discussed in conventional endocrinology or even functional medicine contexts, but which I believe is a critically important component of comprehensive care: integrative chiropractic care.

My clinical observations and emerging research literature support a compelling case for why chiropractic care, specifically as practiced within an integrative, evidence-based framework, is a meaningful and physiologically grounded intervention for women navigating the menopausal transition.

The Autonomic Nervous System Connection: Menopause as an Autonomic Dysregulation Event

One of the most important and underappreciated aspects of menopausal physiology is autonomic nervous system (ANS) dysregulation. The menopausal transition involves profound changes in the balance between the sympathetic (SNS) and parasympathetic (PNS) branches of the ANS, changes that directly contribute to many of the most troubling menopausal symptoms.

Estrogen strongly modulates autonomic tone. It promotes parasympathetic activity, which supports heart rate variability, reduces cardiovascular reactivity, promotes peripheral vasodilation, and supports digestive function. Estrogen withdrawal causes a relative increase in sympathetic dominance, contributing to:

• Elevated resting heart rate and reduced heart rate variability (HRV), the latter being a marker of cardiovascular health and stress resilience.
• Increased vascular resistance and hypertension through elevated norepinephrine and reduced nitric oxide availability.
• Heightened stress reactivity through sensitization of the HPA axis and increased adrenergic responses to stressors.
• Exacerbation of hot flashes through sympathetically mediated peripheral vasoconstriction that impairs heat dissipation, followed by paradoxical vasodilatory surges.
• Sleep disruption through elevated nocturnal sympathetic activity and reduced melatonin production.
• Digestive dysfunction through reduced parasympathetic support for gastric motility, enzyme secretion, and gut-immune interaction.

Chiropractic spinal manipulation has documented effects on autonomic nervous system function. The specific mechanism involves the afferent neural pathways of the somatosensory system that connect the spinal joints and paraspinal tissues to the dorsal horn of the spinal cord, and from there to autonomic regulatory centers in the brainstem (particularly the nucleus tractus solitarius (NTS) and the rostral ventrolateral medulla (RVLM)) and the hypothalamus.

Spinal manipulation generates a burst of proprioceptive and mechanoreceptive afferent input from paraspinal mechanoreceptors (particularly Ruffini corpuscles in facet joint capsules and muscle spindles in paraspinal muscles). This afferent volley has the following autonomic effects:

• Inhibition of sympathetic outflow through interneuronal pathways in the dorsal horn that project to the intermediolateral cell column (IML) of the thoracic spinal cord, where preganglionic sympathetic neurons originate.
• Activation of descending analgesic and autonomic modulating pathways from the periaqueductal gray (PAG) and NTS through the release of endogenous opioids, serotonin, and norepinephrine from brainstem nuclei.
• Normalization of segmental facilitation, the pathological state of hyperexcitability in spinal cord segments corresponding to dysfunctional joints, which, in an ongoing state, causes chronic sympathetic nervous system hyperactivation and contributes to visceral dysfunction.

The clinical implications for menopausal women are significant: regular chiropractic adjustments that reduce sympathetic hypertonicity and restore ANS balance can improve HRV, reduce cardiovascular reactivity, improve sleep quality, reduce the frequency and severity of hot flashes through improved thermoregulatory ANS balance, and reduce the anxiety and stress reactivity that amplify all other menopausal symptoms.

Spinal Alignment and Structural Integrity: The Musculoskeletal Dimension of Menopause

The menopausal transition has profound effects on the musculoskeletal system through multiple mechanisms:

• Bone loss (osteoporosis and osteopenia): Estrogen is the primary regulator of bone resorption. It inhibits osteoclast activity and promotes osteoblast survival. When estrogen falls, osteoclast activity increases dramatically, and bone mineral density falls at an accelerated rate, particularly in the first 5-10 years after menopause. The spine is one of the sites most vulnerable to this accelerated bone loss, with vertebral compression fractures representing a major cause of pain and disability in postmenopausal women.
• Muscle loss (sarcopenia): Both estrogen and testosterone promote muscle protein synthesis and muscle fiber maintenance. Their decline during menopause accelerates sarcopenia, the age-related loss of muscle mass. Paraspinal muscle weakness contributes to spinal instability, altered movement patterns, and increased mechanical stress on spinal joints and discs.
• Ligamentous laxity: Estrogen normally supports collagen synthesis in ligaments and tendons. Its decline increases joint laxity, particularly in the sacroiliac joints and spinal facet joints, contributing to instability, pain, and altered spinal mechanics.
• Intervertebral disc degeneration: The nucleus pulposus of intervertebral discs is dependent on adequate hydration and proteoglycan content for its shock-absorbing and load-distributing function. Estrogen has been shown to support disc cell (annulus fibrosus and nucleus pulposll) function and inhibit disc degeneration. Estrogen withdrawal accelerates disc aging and degeneration.
• Myofascial changes: The global reduction in mitochondrial function and muscle cell energy availability contributes to myofascial trigger point development, reduced muscle extensibility, and chronic muscular tension patterns that alter posture and increase mechanical pain.

Chiropractic care directly addresses these musculoskeletal changes through:

• Spinal manipulation and mobilization that restore normal joint motion, reduce painful joint adhesions, and normalize the mechanical stress distribution across spinal structures.
• Soft tissue therapies (myofascial release, trigger point therapy, instrument-assisted soft tissue mobilization) that address the myofascial component of menopausal musculoskeletal dysfunction.
• Rehabilitative exercise prescription that builds paraspinal and core muscle strength, addressing sarcopenia and supporting spinal structural integrity.
• Postural correction and movement-pattern retraining to reduce mechanical stress on vulnerable spinal structures.
• Nutritional counseling (within the chiropractic scope of practice in relevant jurisdictions, and in collaboration with our medical team) that supports bone, muscle, and connective tissue health.

Chiropractic Care and Neuroinflammation: The Connection to Brain Fog and Mood

Emerging research on the gut-brain axis and the relationship between spinal cord neuroinflammation and central neuroinflammation provides additional mechanistic support for chiropractic care’s role in addressing the cognitive and mood symptoms of menopause.

Spinal facilitation (hyperexcitable spinal cord segments associated with dysfunctional joints) drives chronic neurogenic inflammation through the release of substance P and calcitonin gene-related peptide (CGRP) from C-fiber and A-delta fiber primary afferents. This neurogenic inflammation sensitizes dorsal horn neurons and, through ascending pathways, contributes to central sensitization and neuroinflammation at higher levels of the nervous system.

Central sensitization and neuroinflammation in the mesodiencephalic structures are increasingly recognized as contributors to the brain fog, cognitive dysfunction, and mood disorders associated with menopause. By reducing the peripheral neuroinflammatory load through chiropractic correction of spinal dysfunction, it is possible to reduce the neuroinflammatory burden at central levels.

Furthermore, chiropractic manipulation has been shown to reduce substance P levels in the cerebrospinal fluid and blood, and to acutely modulate the cortisol awakening response, a marker of HPA axis function. Given the HPA axis dysregulation that characterizes the menopausal transition, these effects of chiropractic care are directly relevant.

Chiropractic Care and Gut Health: The Microbiome-Estrogen Connection

The relationship between gut health, the estrobolome (the community of gut bacteria that metabolize estrogens), and menopausal hormone biology is increasingly recognized as clinically important.

Approximately 30-40% of circulating estrogens are excreted into the bile as conjugated forms (glucuronides and sulfates) and then deconjugated in the gut by bacterial beta-glucuronidase and steroid sulfatase enzymes, allowing their reabsorption through the enterohepatic circulation. The composition and activity of the gut microbiome, specifically the estrobolome, therefore directly determines how much estrogen is recycled versus excreted, significantly influencing total estrogen bioavailability.

Dysbiosis (gut microbial imbalance) during menopause can either under-recycle estrogens (contributing to a low-estrogen state) or over-recycle them (contributing to excessive accumulation of estrogen metabolites). Both scenarios are clinically problematic.

The vagus nerve (cranial nerve X) is the primary parasympathetic nerve supplying the gut, and its function is critical for maintaining healthy gut motility, mucosal integrity, and microbiome diversity. Vagal tone is directly influenced by the autonomic balance that chiropractic care supports. By improving vagal tone and reducing sympathetic dominance, chiropractic interventions can support the gut environment that is critical for healthy estrogen metabolism.

Additionally, chiropractic manipulation of the thoracic and lumbar spine directly influences the splanchnic nerve innervation of the digestive organs. The splanchnic nerves carry sympathetic fibers to the liver, pancreas, small intestine, and colon. Normalizing thoracolumbar spinal mechanics reduces aberrant sympathetic input to these organs, supporting optimal function.

The Multidisciplinary Model of Care: Dr. Cardenas and the Injury Medical Clinic PA Team

One of the most important things I want to share in this educational post is how the model of care at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, represents the future of integrative health management for women with complex menopausal presentations.

Dr. Maria Guadalupe Cardenas, MD: Medical Director and Collaborative Physician

At the core of our medical team is Dr. Maria Guadalupe Cardenas, MD, Board-Certified in Internal Medicine, with NPI number 1164426749 and Texas MD License #J2933. Dr. Cardenas brings over 40 years of experience as an internist to our collaborative practice, bringing clinical wisdom and diagnostic expertise invaluable for managing complex, multi-system presentations.

As the Medical Director and Collaborative Physician at Injury Medical Clinic PA, Dr. Cardenas provides:

• Comprehensive internal medicine evaluation and management, bringing decades of experience in cardiovascular medicine, metabolic disease, endocrine disorders, and general internal medicine to every patient case.
• Medical direction and oversight of our clinical protocols, ensuring that all care delivered at the clinic meets the highest standards of evidence-based medicine.
• Collaborative medical decision-making in complex cases, particularly where menopausal symptoms intersect with cardiovascular risk, metabolic disease, thyroid dysfunction, bone health concerns, or other systemic conditions that require internist-level diagnostic expertise.
• Prescription authority for HRT and other pharmaceutical interventions, working in close collaboration with my functional medicine and chiropractic assessment to ensure that hormonal protocols are precisely tailored to each patient’s biological profile.
• Oversight of laboratory interpretation and management of results, particularly for complex metabolic and cardiovascular findings.

My collaboration with Dr. Cardenas is not simply a formal administrative arrangement. It is a genuine clinical partnership built on mutual respect for the expertise each discipline brings to patient care. As an internist with 40 years of experience, Dr. Cardenas brings broad clinical pattern recognition and diagnostic depth that complements the functional medicine and chiropractic approach I bring. Together, we can address the full biological complexity of the menopausal patient in a way neither discipline could achieve alone.

This multidisciplinary setup is the model of care that most effectively serves women with complex menopausal presentations. Hormone prescribing decisions are made with full medical oversight. Robust laboratory data support functional medicine interventions. Chiropractic care is provided with awareness of the patient’s full medical context. We coordinate rehabilitative interventions with nutritional and hormonal protocols to maximize outcomes.

The Comprehensive Care Model at Injury Medical Clinic PA

At Injury Medical Clinic PA, our model integrates multiple disciplines into a coherent, patient-centered approach:

Chiropractic Care (Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST)

• Structural spinal assessment and manipulation
• Functional movement assessment
• Autonomic nervous system evaluation (HRV monitoring, postural challenge testing)
• Trigger point therapy and myofascial release
• Rehabilitative exercise prescription
• Nutritional and nutraceutical consultation
• Functional medicine evaluation and case management

Internal Medicine (Dr. Maria Guadalupe Cardenas, MD)

• Comprehensive physical examination
• Medical history and differential diagnosis
• Laboratory ordering and interpretation
• HRT and pharmaceutical management
• Cardiovascular risk stratification and management
• Medical direction and collaborative oversight

Functional Medicine

• Comprehensive metabolic and nutritional assessment
• Mitochondrial function evaluation
• Gut health and microbiome optimization
• Toxicology screening (heavy metals, environmental toxins)
• Epigenetic and genomic considerations (MTHFR, COMT, APOE genotyping)
• Personalized nutraceutical protocols

Personal Injury Care and Rehabilitation

• Injury assessment and management
• Physical rehabilitation following trauma
• Pain management through integrative approaches
• Functional restoration and return-to-activity protocols

Related Services

• Health coaching and lifestyle medicine
• Stress management and mind-body medicine
• Sleep optimization
• Nutritional counseling

This integrated model means a woman presenting with menopausal symptoms at Injury Medical Clinic PA receives care that addresses not just her hormones, but her neurology, mitochondria, musculoskeletal system, gut health, cardiovascular risk, and complete metabolic profile. This is what comprehensive menopausal care looks like when it is done properly.

The Research Foundation: What the Literature Says About Integrative Menopausal Management

The evidence base for the integrative approach to menopausal management has grown substantially over the past decade. Here I present a structured review of the key research findings that underpin our clinical protocols.

Mitochondrial Dysfunction and NAD+ in Menopause

The 2021 Nature Cell Biology study I referenced earlier documented that NAD+ decline during the menopausal transition accelerates beyond the normal age-related trajectory, with significant implications for mitochondrial function, cellular metabolism, and the symptom burden of menopause. The study demonstrated that restoring NAD+ levels in preclinical menopausal models improved metabolic function, reduced adiposity, improved muscle function, and enhanced cognitive performance (Miao et al., 2021).

Subsequent work has expanded on these findings. Yoshino et al. (2021) published a randomized controlled trial in Science showing that NMN (nicotinamide mononucleotide) supplementation in postmenopausal women improved skeletal muscle insulin sensitivity, muscle mitochondrial biogenesis markers, and physical performance over 10 weeks. This was one of the first human clinical trials to demonstrate that NAD+ precursor supplementation can reverse metabolic consequences of NAD+ depletion in menopausal women.

Amano et al. (2022) demonstrated in preclinical models that NAD+ depletion in hypothalamic neurons specifically impairs thermoregulatory function and increases hot flash-like thermoregulatory events, providing direct mechanistic support for the NAD+-hot flash connection.

Inflammation, Oxidative Stress, and HRT Efficacy

Lobo et al. (2016) in Climacteric reviewed the evidence for the interaction between systemic inflammation and HRT efficacy, concluding that high baseline CRP levels predict poor HRT response and that anti-inflammatory interventions can significantly improve HRT outcomes. This review supported a clinical framework that addresses inflammation as a prerequisite for optimal HRT performance.

Stice et al. (2019) in the Journal of Neuroendocrinology demonstrated that neuroinflammation in the hypothalamic preoptic area directly impairs the estrogenic regulation of thermoregulation, providing mechanistic evidence for why estrogen works less well in the context of neuroinflammation.

Polotsky & Polotsky (2010) reviewed the cardiovascular effects of menopausal oxidative stress and its interaction with HRT in Maturitas, finding that transdermal estradiol (unlike oral estradiol) does not increase oxidative stress markers and may reduce them in certain tissues, supporting the preference for transdermal delivery.

Hypothalamic Insulin Resistance and Menopausal Weight Gain

Clegg et al. (2006) published landmark research in Diabetes showing that estrogen receptor alpha (ER?) knockout in the hypothalamus in rodents reproduced the metabolic phenotype of menopause, including increased food intake, decreased energy expenditure, and visceral fat accumulation, independent of peripheral hormonal effects. This study established that central (hypothalamic) insulin and estrogen resistance is a primary driver of menopausal metabolic dysfunction, not simply a consequence of peripheral hormonal changes.

Lizcano & Guzmán (2014) in ISRN Obstetrics and Gynecology reviewed the central insulin resistance hypothesis of menopausal metabolic syndrome and provided clinical guidance for management through both hormonal and metabolic interventions.

Lovejoy et al. (2008) in Obesity Reviews published a comprehensive review of the determinants of menopausal weight gain, concluding that the shift to visceral fat distribution cannot be explained by caloric intake or physical activity changes alone, and must be understood as a primary metabolic consequence of ovarian hormone decline and its effects on central energy homeostasis.

Magnesium and Menopausal Symptom Management

De Souza et al. (2000), in the Journal of Women’s Health & Gender-Based Medicine, conducted a randomized trial of magnesium supplementation in perimenopausal women and found significant reductions in hot flash frequency and improved sleep quality compared with placebo. The authors attributed this to magnesium’s effects on NMDA receptor function and thermoregulatory stability.

Abbasi et al. (2012) in the Journal of Research in Medical Sciences demonstrated that magnesium supplementation improved sleep quality, reduced nocturnal awakening, and reduced insomnia severity in elderly individuals with insomnia, with mechanisms attributed to melatonin regulation and NMDA receptor modulation.

Vitamin D and Menopausal Outcomes

Lips & van Schoor (2011) in Best Practice & Research Clinical Endocrinology & Metabolism reviewed the evidence for vitamin D in menopausal bone health, finding that vitamin D3 supplementation of at least 800-1000 IU daily significantly reduces fracture risk when combined with adequate calcium, with additional benefits for muscle function, insulin sensitivity, and mood.

Shaffer et al. (2020) analyzed data from the Women’s Health Initiative in Menopause. They found that women with higher vitamin D intake had significantly lower rates of depression, cognitive decline, and cardiovascular events, supporting the multisystemic importance of adequate vitamin D in the menopausal population.

Chiropractic Care and Autonomic Function

Welch & Boone (2008), in the Journal of Chiropractic Medicine, found that cervical and thoracic spinal manipulation significantly reduced sympathetic tone (measured by skin conductance and heart rate variability) and increased parasympathetic activity in study participants. This provides mechanistic support for chiropractic care’s role in normalizing the ANS.

Budgell & Polus (2006), in the Journal of Manipulative and Physiological Therapeutics, reported that thoracic spinal manipulation produced significant changes in HRV, specifically increasing the high-frequency power (HF) component that reflects parasympathetic tone and decreasing the low-frequency/high-frequency (LF/HF) ratio that indicates sympathetic dominance.

Sampath et al. (2017) published a systematic review of chiropractic manipulation and autonomic function in Chiropractic & Manual Therapies, finding consistent evidence that spinal manipulation modulates ANS function by reducing sympathetic dominance and enhancing parasympathetic activity, with effects persisting for at least 24- 48 hours post-treatment.

Taurine and Mitochondrial Function

Schaffer et al. (2014) in Amino Acids provided a comprehensive review of taurine’s role in mitochondrial function, including the discovery that taurine modification of mitochondrial tRNA is essential for proper translation of ETC subunits. Taurine deficiency was shown to cause ETC dysfunction and reduced ATP production that could be reversed by taurine supplementation.

Jong et al. (2012) in Amino Acids demonstrated that taurine supplementation in aging animals reversed mitochondrial dysfunction in multiple tissues, improved exercise capacity, and reduced oxidative stress markers, with implications for the aging and menopausal contexts.

The Methylation-Estrogen Metabolism Connection

Zhu & Conney (1998), in Carcinogenesis, established the critical role of COMT-mediated methylation in converting catecholestrogens (4-hydroxy and 2-hydroxy estrogens) to their methoxy forms, which are biologically benign and even anticarcinogenic, in contrast to unmethylated catecholestrogens that can form DNA adducts.

Yager & Davidson (2006), in the New England Journal of Medicine, reviewed estrogen carcinogenesis and confirmed that the balance between 2-OH and 4-OH estrogen metabolites, and between their methylated and unmethylated forms, critically determines breast cancer risk. Methylation support (through adequate B6, folate, and B12) was identified as a modifiable factor in optimizing estrogen metabolism.

Understanding HRT Monitoring: Laboratory Parameters and Clinical Decision Points

One of the most important clinical skills in HRT management is knowing what to measure, when, and what the results mean for dose adjustment.

Estradiol Monitoring: The Target Window

Serum estradiol monitoring at 6 weeks after initiating or adjusting transdermal estradiol provides critical information about whether the dose is appropriate. My clinical thresholds are:

• Estradiol above 100 pg/mL: The dose is almost certainly too high. Clinical signs of excess estrogen may include breast tenderness, fluid retention, headaches, mood swings, and potentially worsening hot flashes (counterintuitive but possible through receptor desensitization). Lower the dose and recheck in 6 weeks.
• Estradiol below 30 pg/mL: The dose is likely insufficient for symptom control in most women. If symptoms persist (hot flashes, vaginal dryness, brain fog), consider increasing the dose and rechecking in 6 weeks.
• Estradiol between 30-100 pg/mL: This is the target window for most symptomatic menopausal women. The specific optimal level within this range is individual and symptom-guided.

FSH and LH: Confirming Menopausal Status and Assessing Suppression

FSH (follicle-stimulating hormone) and LH (luteinizing hormone) are elevated in menopause (typically FSH >40 mIU/mL and LH >20-30 mIU/mL) due to the loss of negative feedback from ovarian estrogen and inhibin. These levels confirm menopausal status and provide a baseline.

With adequate HRT, FSH and LH will typically decrease from their menopausal peaks, reflecting the restored negative feedback. Monitoring these markers indirectly confirms that exogenous estrogen is achieving a tissue-level effect.

The SHBG Consideration in Estrogen Bioavailability

SHBG (sex hormone-binding globulin) binds both estradiol and testosterone with high affinity, limiting their free (bioavailable) fraction. Only free estradiol and free testosterone can bind to and activate their receptors. SHBG levels are:

• Elevated by: oral estradiol (much more so than transdermal), thyroid hormone, high carbohydrate intake, high body fat (through increased aromatase activity and adipokine signaling).
• Reduced by: insulin resistance, high androgens, obesity, hypothyroidism.

In women with high SHBG, even adequate total estradiol levels may result in insufficient free estradiol for symptom control. In these cases, clinical assessment of symptoms, boron supplementation (which reduces SHBG), and potentially adjusting estradiol dose based on calculated free estradiol or free androgen index is appropriate.

Progesterone Monitoring

Progesterone levels should be checked approximately 1-2 weeks after the initiation or dose change of oral progesterone, in the morning (reflecting the previous night’s bedtime dose and the subsequent metabolic clearance). Target levels for symptom control and endometrial protection are typically in the range of 1-10 ng/mL in the luteal equivalent phase (though the specific target for a given woman depends on her clinical picture and the dose of estrogen she is taking, as adequate progesterone must be maintained relative to estrogen to prevent endometrial hyperplasia).

DHEA-S: The Adrenal Reserve Marker

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated circulating storage form of DHEA and reflects adrenal DHEA production. In menopausal women:

• Normal DHEA-S ranges decline with age; typical reference ranges for postmenopausal women are 25-200 mcg/dL, compared to peak values of 200-450 mcg/dL in the 20s-30s.
• Levels below 50 mcg/dL suggest significant adrenal DHEA depletion and are associated with fatigue, low libido, impaired immune function, and accelerated aging.
• With DHEA supplementation, recheck levels at 6 weeks and adjust the dose to reach the mid-normal range for a premenopausal woman of comparable age.

Integrating the Full Protocol: A Personalized Approach to Menopausal Biological Optimization

The clinical framework I use at Injury Medical Clinic PA integrates these elements into a coherent, phased, personalized protocol. Here is how I think about structuring care for a new menopausal patient.

Phase 1: Assessment and Foundation Building (Weeks 1-2)

Goals:

• Establish complete biological baseline through comprehensive laboratory testing.
• Identify specific deficiencies, inflammatory burdens, and metabolic dysfunctions.
• Begin foundational micronutrient protocol to address the most critical deficiencies.
• Initiate chiropractic assessment and address any acute musculoskeletal dysfunctions.
• Establish cardiovascular and metabolic baseline in collaboration with Dr. Cardenas.

Key interventions:

• Comprehensive laboratory panel (as described above).
• Begin magnesium glycinate (300-400 mg at bedtime to start).
• Begin methylated B complex.
• Begin vitamin D3 with K2 (dose guided by baseline 25-OH vitamin D level).
• Begin omega-3 fatty acids (EPA/DHA 2-3g/day for anti-inflammatory foundation).
• Initial chiropractic evaluation and treatment.
• Medical evaluation with Dr. Cardenas.

Phase 2: HRT Initiation and Titration (Weeks 2-16)

Goals:

• Initiate HRT based on symptom profile and laboratory findings, with a medical prescription from Dr. Cardenas.
• Apply the 14-day rule rigorously.
• Monitor and manage side effects systematically.
• Recheck labs at 6 weeks post-initiation.

Key interventions:

• Transdermal estradiol initiation (starting dose typically 0.05-0.075 mg/day, adjustable based on serum levels).
• Oral micronized progesterone at bedtime (100 mg for endometrial protection with low-dose estrogen; 200 mg if using higher estrogen doses).
• DHEA (5-25 mg in the morning, individualized to baseline DHEA-S level and symptom profile).
• Continue and expand the nutraceutical protocol, including taurine, zinc, boron, and potassium.
• Continuation and progression of chiropractic care, with focus on thoracic spine and cervical spine for ANS normalization.
• Regular follow-up with Dr. Cardenas for medical oversight.

Phase 3: Optimization and Stabilization (Weeks 16-52)

Goals:

• Achieve stable symptom control with minimal side effects.
• Optimize metabolic function (insulin sensitivity, mitochondrial function, inflammatory markers).
• Support musculoskeletal health and physical function.
• Address any residual symptoms through targeted interventions.

Key interventions:

• NAD+ precursor support (NMN or NR supplementation) to directly address the NAD+ depletion documented in the research literature.
• Mitochondrial support protocol (CoQ10 as ubiquinol, PQQ, alpha-lipoic acid, acetyl-L-carnitine) to support ETC function and mitochondrial biogenesis.
• Advanced gut health assessment and optimization if gut-related symptoms or estrobolome dysfunction is suspected.
• Continued chiropractic care with progression to maintenance and functional movement focus.
• Repeat comprehensive laboratory assessment at 6 months.

Phase 4: Maintenance and Long-Term Optimization (Ongoing)

Goals:

• Maintain biological optimization across all measured parameters.
• Support healthy aging, bone integrity, cardiovascular function, and cognitive health.
• Adjust protocols as biological needs evolve.
• Prevent long-term complications of menopausal hormonal and metabolic changes.

Key interventions:

• Annual comprehensive laboratory reassessment.
• Ongoing HRT management with Dr. Cardenas.
• Ongoing chiropractic maintenance care.
• Ongoing nutraceutical protocol with adjustments based on annual labs.
• Lifestyle medicine support (exercise prescription, dietary guidance, sleep optimization, stress management).

The Broader Context: Menopause, Cardiovascular Disease, and Long-Term Health

No comprehensive discussion of menopausal health management would be complete without addressing the long-term health consequences of inadequately managed menopausal biology. The biological disruptions I have described above, if left unaddressed, have serious long-term health implications.

Cardiovascular Disease: The Leading Killer of Postmenopausal Women

Cardiovascular disease (CVD) is the leading cause of mortality in postmenopausal women, and the menopausal transition is associated with a dramatic acceleration of cardiovascular risk. This is not coincidental. The biological changes of menopause directly drive cardiovascular pathology through multiple mechanisms:

• Estrogen withdrawal removes estrogen’s vasodilatory, anti-inflammatory, and antioxidant effects on the vascular endothelium. The endothelium becomes less efficient at producing NO, more susceptible to oxidative damage, and more prone to inflammatory activation.
• Sympathetic dominance and reduced HRV (as described above) increase resting heart rate and blood pressure variability, two independent cardiovascular risk factors.
• Insulin resistance and dyslipidemia emerge or worsen, with increases in LDL-C, LDL particle number, oxidized LDL, and VLDL triglycerides, and decreases in cardioprotective HDL2b particles.
• Visceral adiposity promotes systemic inflammation and cardiovascular risk through the adipokine and inflammatory mechanisms described above.
• Homocysteine elevation from methylation impairment damages endothelial cells and promotes thrombosis.

The evidence from the Nurses’ Health Study and other large prospective cohorts shows that women who initiate HRT within 10 years of menopause or before age 60 have significantly reduced cardiovascular event rates compared to women who do not use HRT or who initiate it later (the “timing hypothesis” or “window of opportunity” for HRT). The Women’s Health Initiative (WHI), which initially raised concerns about HRT and cardiovascular risk, used oral conjugated equine estrogen (which raises CRP and clotting factors) in women who were an average of 63 years old (many of whom already had established atherosclerosis). The cardiovascular risk seen in the WHI does not apply to younger, recently menopausal women using transdermal estradiol, as multiple subsequent analyses and meta-analyses have demonstrated.

The integrative approach at Injury Medical Clinic PA, with its emphasis on reducing inflammation, improving ANS balance through chiropractic care, optimizing methylation, correcting insulin resistance, and providing appropriate HRT (transdermal, at the right time), directly addresses the cardiovascular risk profile of menopausal women comprehensively.

Cognitive Decline and Dementia: The Neurological Stakes

Estrogen plays a critical neuroprotective role in the brain. Its effects include:

• Promotion of synaptic density and plasticity through BDNF upregulation and dendritic spine maintenance in the hippocampus and prefrontal cortex.
• Anti-amyloid effects: Estrogen promotes the non-amyloidogenic processing of APP (amyloid precursor protein) through the alpha-secretase pathway, reducing amyloid-beta production and aggregation.
• Anti-tau effects: Estrogen promotes tau phosphatase activity, reducing tau hyperphosphorylation that leads to neurofibrillary tangle formation.
• Mitochondrial neuroprotection: As described, estrogen supports NAD+ synthesis and mitochondrial biogenesis in neurons.
• Neuroinflammation regulation: Estrogen receptor signaling in microglia promotes their anti-inflammatory M2 phenotype and reduces neuroinflammatory activation.

When estrogen is withdrawn during menopause, all of these neuroprotective functions are impaired. Decades of research on the Critical Window Hypothesis for estrogen and dementia suggest that women who use HRT during the perimenopausal window have significantly reduced rates of Alzheimer’s disease and other dementias compared to those who never use HRT or who start it late, when neurological damage has already been established.

The mitochondrial dysfunction and NAD+ depletion of menopause are also directly relevant to cognitive aging, given the brain’s extreme energetic demands. Combining HRT (to restore estrogenic neuroprotection) with mitochondrial support (NAD+ precursors, CoQ10, mitochondria-targeted antioxidants) and anti-inflammatory interventions offers the most comprehensive approach to protecting cognitive health during the menopausal transition.

Bone Health: Preventing the Osteoporotic Fracture Epidemic

Osteoporosis affects approximately 10 million American women, with another 43 million having low bone mass (osteopenia) that puts them at increased fracture risk. The majority of this burden falls on postmenopausal women, for whom the accelerated bone loss of the early postmenopausal years is the primary driver.

The integrative approach to bone health maintenance at Injury Medical Clinic PA includes:

• HRT as first-line bone protection: Estrogen directly inhibits osteoclastic bone resorption and is the most effective and physiologically appropriate bone protection for recently menopausal women.
• Vitamin D3 and K2 for calcium metabolism optimization.
• Magnesium and boron for their direct roles in bone mineralization and PTH/vitamin D metabolism.
• Weight-bearing exercise and resistance training, prescribed through our rehabilitation and chiropractic program, which is the most effective non-pharmacological stimulus for bone formation through mechanical loading.
• Chiropractic care to maintain spinal mobility and reduce fall risk through improved balance, proprioception, and neuromuscular coordination, all of which reduce the risk of osteoporotic fractures.

The HPA Axis, Cortisol, and Adrenal Function in Menopause

One dimension of menopausal biology that deserves extended discussion is the hypothalamic-pituitary-adrenal (HPA) axis and the role of cortisol in menopausal physiology.

Estrogen and HPA Axis Regulation

Estrogen normally exerts inhibitory feedback on the HPA axis at multiple levels, reducing the amplitude of the cortisol stress response and promoting faster cortisol recovery after stress. Women generally have a more regulated stress response during their reproductive years compared to postmenopausal women, in part because of estrogen’s HPA-moderating effects.

When estrogen falls during menopause, this inhibitory regulation is lost, and the HPA axis becomes more reactive. The result is:

• Elevated baseline cortisol and elevated evening cortisol (when it should be at its daily nadir).
• Exaggerated cortisol responses to stressors that previously would have been manageable.
• Slower cortisol recovery after stress exposure.
• Impaired negative feedback, meaning that cortisol levels remain elevated longer after stress before they return to baseline.

Chronically elevated cortisol has profound negative effects on menopausal health:

• Insulin resistance amplification: Cortisol is a potent antagonist of insulin action in both peripheral tissues and the hypothalamus, directly worsening the insulin resistance already driven by estrogen deficiency.
• Visceral fat deposition: Cortisol promotes preferential fat deposition in the visceral adipose depot through the high density of glucocorticoid receptors in visceral adipocytes.
• Muscle catabolism: Elevated cortisol promotes protein breakdown in skeletal muscle, directly worsening sarcopenia.
• Bone loss: Cortisol directly suppresses osteoblast function and promotes osteoclast activity, accelerating osteoporosis.
• Immune suppression: While acute cortisol is immunoprotective, chronic elevation suppresses cellular immunity, increasing vulnerability to infections and impairing cancer surveillance.
• Neurological damage: Chronic cortisol elevation causes dendritic retraction in the hippocampus, reduces hippocampal neurogenesis, and damages the prefrontal cortex, directly contributing to brain fog, memory impairment, and mood disorders.
• NAD+ depletion: Cortisol activates CD38 and PARP, both NAD+-consuming enzymes, accelerating NAD+ depletion already occurring due to estrogen withdrawal.

Addressing HPA Dysregulation in Our Integrative Protocol

The HPA axis dysregulation of menopause is addressed through multiple elements of our integrative protocol:

• HRT itself partially restores the HPA regulatory effects of estrogen, but the effect is gradual and incomplete. Adding DHEA is important because DHEA and cortisol are inversely related in many respects; DHEA is an antiglucocorticoid that buffers cortisol’s negative effects at the cellular level.
• Magnesium is one of the most potent physiological modulators of the HPA axis. Magnesium deficiency is associated with HPA hyperreactivity, and magnesium supplementation has been shown to reduce cortisol responses to psychological stressors.
• Phosphatidylserine (100-300 mg/day) has documented HPA-blunting effects and can reduce cortisol responses to physical and psychological stress.
• Adaptogenic botanicals such as Rhodiola rosea, Withania somnifera (ashwagandha), and Eleutherococcus senticosus (eleuthero) have documented effects on cortisol regulation and HPA axis normalization.
• Chiropractic care, through its ANS-modulating effects, reduces the tonic sympathetic hyperactivation that amplifies HPA axis reactivity.
• Sleep optimization is critical because sleep is the primary period of HPA axis recovery. Sleep disruption (itself amplified by HPA dysregulation, creating another vicious cycle) prevents the nocturnal cortisol suppression and DHEA surge essential for HPA recovery.

Sleep Architecture Disruption in Menopause: Biology, Consequences, and Solutions

Sleep disruption is among the most debilitating and consequential symptoms of menopause. Estimates suggest that 40-60% of perimenopausal and postmenopausal women experience significant sleep disturbance, including increased sleep onset latency, frequent nocturnal awakenings, early morning awakening, and reduced total sleep time.

The Biology of Menopausal Sleep Disruption

The mechanisms are multiple and interconnected:

• Hot flashes and night sweats directly disrupt sleep by causing awakenings and discomfort. Even hot flashes that do not cause full awakening can trigger electroencephalographic (EEG) arousal, fragmenting sleep architecture and reducing slow-wave sleep (SWS, the most restorative sleep stage).
• Progesterone deficiency removes a major sleep-promoting neurosteroid. As described above, progesterone metabolizes into allopregnanolone, a potent positive allosteric modulator of GABA-A receptors. Its absence impairs sleep quality and increases nighttime anxiety.
• HPA axis dysregulation elevates nocturnal cortisol, which fragments SWS and suppresses growth hormone (GH) secretion (highest during the first SWS episode of the night). Reduced GH impairs tissue repair, body composition, and metabolic recovery during sleep.
• Estrogen deficiency reduces serotonin availability, which is important for sleep regulation because serotonin is a precursor to melatonin. Serotonin is converted to melatonin by N-acetyltransferase in the pineal gland, and low serotonin means low melatonin substrate, contributing to both impaired sleep onset and impaired circadian rhythmicity.
• Mitochondrial dysfunction in sleep-regulatory neurons in the ventrolateral preoptic nucleus (VLPO) impairs their capacity to generate the inhibitory output that suppresses the wake-promoting systems (the ascending arousal systems: the locus coeruleus, raphe nuclei, and tuberomammillary nucleus) during sleep.
• Musculoskeletal pain, frequently present in menopausal women due to the structural changes I described above, is a major cause of nighttime awakening and impaired sleep consolidation.

Sleep Optimization in Our Integrative Protocol

Sleep quality is not a luxury. It is a biological necessity, and inadequate sleep directly worsens every other aspect of menopausal biology. Our protocol for menopausal sleep optimization includes:

• Bedtime oral micronized progesterone (100-200 mg), leveraging allopregnanolone’s GABA-A modulating effects for sleep promotion.
• Magnesium glycinate or threonate at bedtime (200-400 mg), for NMDA receptor modulation and reduction of nocturnal cortisol.
• Taurine (500-1500 mg at bedtime) for GABA-A receptor enhancement and general neurological calming.
• Melatonin (0.3-3 mg, 30-60 minutes before bedtime): low-dose melatonin is more physiologically appropriate than the high doses (5-10 mg) commonly self-prescribed.
• Glycine (3g at bedtime) has documented sleep-quality-improving effects through core body temperature cooling via peripheral vasodilation) and NMDA receptor modulation in the hypothalamic sleep regulatory system.
• Eliminate blue light in the 2 hours before bedtime, as blue light (450-490 nm wavelength) maximally suppresses melatonin production through melanopsin-expressing intrinsically photosensitive retinal ganglion cells (ipRGCs).
• Temperature regulation: Sleeping in a cool environment (65-68°F) supports the core body temperature decline required for sleep onset and maintenance, which is particularly important for women experiencing hot flashes and night sweats.
• Chiropractic care addresses musculoskeletal pain that disrupts sleep and supports ANS balance that promotes parasympathetic dominance during sleep.

Thyroid Function and Its Intersection With Menopausal Biology

Thyroid dysfunction is significantly more prevalent in menopausal women than in the general population, and the interaction between thyroid status and menopausal biology is clinically important.

Why Thyroid Function Is Vulnerable During the Menopausal Transition

• Autoimmune thyroid disease (Hashimoto’s thyroiditis) peaks in perimenopausal women, likely due to the immune modulation that accompanies estrogen withdrawal. Estrogen normally promotes a Th2-dominant immune pattern that suppresses thyroid autoimmunity; its decline shifts the balance toward Th1 dominance and autoimmune activation.
• Elevated thyroid-stimulating hormone (TSH) responses to the same free thyroid hormone levels are seen in hypothalamic-pituitary aging, meaning that the hypothalamic-pituitary system requires higher TSH levels to maintain the same thyroid output.
• Impaired T4-to-T3 conversion due to zinc deficiency (as described above), selenium deficiency, and reduced hepatic deiodinase activity.
• Excess reverse T3 (rT3) production from the preferential conversion of T4 to the inactive rT3 form during periods of chronic stress (elevated cortisol) and caloric restriction, which is common in menopausal women trying to manage weight.

The Clinical Consequence of Hypothyroidism Masquerading as Menopause

Many of the classic symptoms of hypothyroidism (fatigue, weight gain, brain fog, depression, constipation, dry skin, cold intolerance, hair loss) are essentially identical to common menopausal symptoms. This creates a significant clinical challenge and a real risk of underdiagnosis: hypothyroid menopausal women may have their thyroid symptoms attributed entirely to menopause and go untreated for their thyroid condition.

This is why I use a comprehensive thyroid panel (TSH, free T3, free T4, reverse T3, thyroid peroxidase antibodies, thyroglobulin antibodies) rather than TSH alone when evaluating all menopausal women. The collaboration with Dr. Cardenas is particularly valuable here, given her 40+ years of internal medicine experience with thyroid disorders and her ability to contextualize laboratory findings within the full clinical picture.

Environmental Toxins, Endocrine Disruption, and the Menopausal Burden

The role of environmental endocrine-disrupting chemicals (EDCs) in the menopausal experience deserves specific attention, particularly in an era of increasing chemical exposures.

EDCs are exogenous chemicals that interfere with hormonal signaling. Relevant categories for menopausal women include:

• Xenoestrogens (bisphenol A/BPA, phthalates, parabens, certain pesticides): compounds that bind to estrogen receptors and exert estrogen-like effects at inappropriate times and doses, disrupting the normal estrogen signaling environment.
• Thyroid-disrupting chemicals (perchlorate, brominated flame retardants, PFAS compounds): compounds that interfere with thyroid hormone synthesis, binding, or metabolism.
• Heavy metals (mercury, lead, arsenic, cadmium): metals that damage mitochondrial function, impair enzyme activity, and promote oxidative stress.

The mitochondrial effects of heavy metals are particularly relevant to menopausal mitochondrial dysfunction. Mercury specifically damages Complex I and Complex IV of the electron transport chain. Lead inhibits delta-aminolevulinic acid dehydratase, impairing heme synthesis that is required for cytochrome b (Complex III), cytochrome c, and cytochrome oxidase (Complex IV). Arsenic uncouples oxidative phosphorylation by substituting for phosphate in ATP synthesis reactions.

At Injury Medical Clinic PA, we assess EDC and heavy metal burden in women with significant unexplained symptom burdens or poor responses to conventional menopausal interventions through urine organic acids testing, hair element analysis, and urine toxic metal screening.

Personalized Medicine and Genomics in Menopausal Care

The emerging field of nutrigenomics and pharmacogenomics has added an important dimension to menopausal care, allowing protocols to be personalized based on an individual’s genetic predispositions.

Key Genetic Variants Relevant to Menopausal Management

MTHFR (C677T and A1298C polymorphisms)

As detailed above, these variants reduce methylenetetrahydrofolate reductase activity, impairing folate methylation and potentially leading to elevated homocysteine, poor estrogen metabolism, and impaired neurotransmitter synthesis. Women with these variants require methylfolate rather than folic acid.

COMT (Val158Met polymorphism)

The catechol-O-methyltransferase (COMT) enzyme methylates catecholamines (dopamine, norepinephrine) and catecholestrogens. The Val158Met variant significantly reduces COMT activity (by approximately 40% in heterozygotes and 75% in homozygotes). Women with this variant:

• Accumulate more catecholamines, making them more prone to anxiety, stress sensitivity, and difficulty with cortisol regulation.
• Accumulate more 4-hydroxyestrogen metabolites, potentially increasing breast cancer risk with exogenous estrogen use.
• Benefit from: adequate magnesium and SAM support for COMT activity, stress management, and potentially modified estrogen metabolism strategies.

APOE (Apolipoprotein E polymorphisms)

The APOE4 allele, carried by approximately 25% of the population in one copy, is the most significant genetic risk factor for Alzheimer’s disease and also affects lipid metabolism and cardiovascular risk. In APOE4 carriers, the neuroprotective benefits of estrogen are complex, with some evidence suggesting differential responses to HRT. This underscores the importance of individualized assessment in menopausal care.

CYP1B1 and CYP1A2 Polymorphisms

These cytochrome P450 enzymes are involved in estrogen metabolism, specifically in the hydroxylation of estrogens to their catechol metabolites. Variants that increase CYP1B1 activity relative to CYP1A2 favor 4-hydroxyestrogen production over 2-hydroxyestrogen production, shifting the estrogen metabolite balance in a less favorable direction. Women with these variants benefit from enhanced COMT support and potentially from DIM (diindolylmethane) or I3C (indole-3-carbinol) supplementation, which shifts estrogen metabolism toward 2-hydroxylation.

Mind-Body Medicine and the Psychoneuroimmunology of Menopause

No comprehensive discussion of menopausal health would be complete without acknowledging the profound role of psychological and social factors in the menopausal experience, and the biological pathways through which these factors influence physiological outcomes.

The Psychoneuroimmunology of Menopausal Stress

Chronic psychological stress during the menopausal transition creates a vicious cycle of biological deterioration through psychoneuroimmunological mechanisms:

• Perceived stress activates the HPA axis and SNS, elevating cortisol and catecholamines.
• Cortisol and norepinephrine promote pro-inflammatory gene expression through NF-?B activation in immune cells, directly increasing the inflammatory cytokine burden.
• Elevated inflammation worsens hot flashes, brain fog, mood disorders, and sleep disruption.
• Worsened symptoms increase perceived stress, completing the cycle.

Social isolation, which is disproportionately experienced by menopausal women (through retirement, children leaving home, relationship transitions, and the social stigma that still surrounds menopause in many cultures), has direct immunological consequences. Research by John Cacioppo and colleagues demonstrated that social isolation upregulates the conserved transcriptional response to adversity (CTRA), a gene expression pattern characterized by elevated pro-inflammatory gene expression and reduced antiviral gene expression, which directly worsens the inflammatory burden.

The clinical implication is that psychological support, social connection, stress management skills, and addressing the meaning-making aspects of the menopausal transition are not soft or secondary interventions. They are biologically active interventions that modify gene expression and inflammatory phenotype.

At Injury Medical Clinic PA, we recognize this dimension of care and integrate it through our health coaching services, our empathetic clinical communication, and our collaborative care model in which patients feel genuinely heard and supported rather than dismissed.

Practical Clinical Observations From My Practice: What I See Every Day

Drawing from my clinical experience at chiropracticscientist.com and the observations I have shared through my professional work and on my LinkedIn profile (linkedin.com/in/dralexjimenez/), I want to share some of the most consistent and clinically meaningful patterns I observe in my menopausal patients.

The “HRT Is Working, But I Still Feel Terrible” Presentation

This is perhaps the most common presentation I see in women who have been in the conventional medical system for their menopausal care. They are on HRT, their estradiol levels are within range, and their OBGYN or primary care physician says everything looks good. But they feel terrible. They are exhausted, they are gaining weight, they are anxious, and they have brain fog. They have been told to give it more time, or have been referred to a psychiatrist for antidepressants.

When I evaluate these women through a comprehensive functional medicine lens, the consistent findings are:

• Elevated hsCRP and inflammatory markers, often with elevated homocysteine.
• Suboptimal magnesium status (RBC magnesium in the lower quartile of reference range).
• Vitamin D deficiency or insufficiency (25-OH vitamin D typically below 40 ng/mL).
• Elevated HOMA-IR (insulin resistance index), often with fasting insulin above 10 mcIU/mL even when fasting glucose is normal.
• Suboptimal DHEA-S
• Poor methylation markers (elevated homocysteine, methylmalonic acid, or positive MTHFR genotyping).
• Spinal dysfunction and reduced HRV on autonomic assessment.

The intervention that reliably helps these women is not more HRT. It is addressing the inflammatory, mitochondrial, and metabolic foundations that are preventing their existing HRT from working effectively.

The “I Don’t Want to Take Hormones, Can I Do Something Natural?” Presentation

I respect every woman’s autonomy regarding her own body and health care decisions. At the same time, I am committed to providing accurate scientific information rather than validating preferences that may not optimally support a patient’s health.

The science is clear that for women who are symptomatic and who do not have genuine contraindications to HRT (recent history of estrogen receptor-positive breast cancer, active thrombotic disease, active liver disease), HRT is the most effective and most well-studied intervention for menopausal symptoms and long-term health protection. The fear of HRT that was created by the 2002 WHI publication has been extensively revised in the subsequent two decades, and the current evidence strongly supports the use of body-identical HRT (transdermal estradiol and micronized progesterone) as a first-line intervention for recently menopausal, symptomatic women.

That said, the foundational biological interventions (mitochondrial support, micronutrient optimization, inflammatory reduction, chiropractic care) provide real benefit regardless of HRT status and should be part of every menopausal woman’s care plan. They are not alternatives to HRT; they are complements to it, and for women who genuinely cannot use HRT, they represent the most evidence-based approach available to them.

The “I Was Fine and Then Perimenopause Hit Like a Truck” Presentation

Perimenopause, the transitional phase before the final menstrual period, is clinically important and yet frequently unrecognized and undertreated. Women may still be having periods, sometimes even regular periods, while experiencing profound hormonal fluctuations, beginning mitochondrial decline, and all of the symptom consequences thereof.

The characteristic feature of perimenopause is hormonal volatility: estrogen levels may swing dramatically up and down within a single menstrual cycle, sometimes reaching very high levels (causing symptoms of estrogen dominance: breast tenderness, bloating, heavy periods) and then crashing low (causing hot flashes, mood instability, insomnia). FSH, which rises progressively as ovarian follicular reserve declines, may be intermittently elevated or still in the premenopausal range.

The practical clinical challenge of perimenopause is that HRT dosing is more complex because the ovaries are still producing variable amounts of estrogen, and adding fixed-dose exogenous estrogen to this variable endogenous production can cause estrogen excess symptoms. The approach I use in collaboration with Dr. Cardenas emphasizes:

• Starting with lower doses of transdermal estradiol, with frequent symptom monitoring.
• Prioritizing progesterone in early perimenopause, when progesterone deficiency (from inadequate ovulation or luteal phase deficiency) is often the primary hormonal imbalance before estrogen deficiency becomes dominant.
• Robust foundational micronutrient and mitochondrial support from the earliest stages of the menopausal transition, before the hormonal disruption has had time to compound the biological damage.
• Chiropractic care and ANS optimization as a high-priority early intervention to preserve HRV, manage stress reactivity, and support the nervous system’s adaptational capacity through the hormonal transition.

The Role of Exercise in Menopausal Biological Optimization

Exercise is one of the most powerful biological interventions for menopausal women, with effects that complement and amplify every other element of the integrative protocol.

Resistance Training and Bone-Muscle-Metabolic Health

Resistance training (progressive overload exercise with free weights, machines, or bodyweight) is the single most effective non-pharmacological intervention for:

• Preventing sarcopenia: Resistance training is the only stimulus that reliably increases muscle protein synthesis and maintains or increases muscle mass in menopausal women. It also increases androgen receptor expression in muscle, amplifying the effects of endogenous and exogenous androgens.
• Improving insulin sensitivity: A single bout of resistance exercise increases GLUT4 transporter translocation to muscle cell membranes through an AMPK (AMP-activated protein kinase)-dependent mechanism, independent of insulin signaling. This effectively bypasses the insulin resistance problem and improves glucose disposal.
• Promoting mitochondrial biogenesis: Exercise activates PGC-1? (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, through AMPK and SIRT1 (which requires NAD+). Regular resistance training increases mitochondrial density, ETC function in skeletal muscle.
• Supporting bone health: Mechanical loading of bone through resistance exercise activates osteocytes (bone-embedded mechanosensors) that signal osteoblasts to increase bone formation.
• Reducing visceral fat: Increased muscle mass from resistance training raises resting metabolic rate and shifts body composition toward lean mass over time.

High-Intensity Interval Training and NAD+ Restoration

High-intensity interval training (HIIT) generates the most powerful AMPK and PGC-1? activating signal of any exercise modality because it rapidly cycles between high metabolic demand (depleting ATP and raising AMP/ATP ratios, which triggers AMPK) and recovery. This translates to the most potent mitochondrial biogenesis and metabolic adaptation signal available through exercise.

Critically, HIIT also activates NAMPT (the rate-limiting enzyme of NAD+ biosynthesis) in skeletal muscle, directly supporting NAD+ restoration. This provides a non-supplemental avenue to restore the NAD+ pool depleted during menopause partially.

Zone 2 Aerobic Training and Mitochondrial Efficiency

Zone 2 training (steady-state aerobic exercise at 60-70% of maximum heart rate, where the primary fuel is fat oxidation) is an important complement to resistance and HIIT training for menopausal women because:

• It primarily trains slow-twitch (Type I) oxidative muscle fibers, which depend most on mitochondrial function and are the first to be affected by mitochondrial decline.
• It promotes fat oxidation capacity, directly addressing the impaired lipolysis of the insulin-resistant menopausal metabolic state.
• It has the most favorable effects on the lipid profile of any exercise modality, particularly for raising HDL2b and reducing small dense LDL particle number.
• It supports mitochondrial quality control through its effects on mitophagy (the selective removal of damaged mitochondria) and mitochondrial fusion and fission dynamics.

At Injury Medical Clinic PA, exercise prescription is a collaborative effort: I assess the patient’s current physical capacity, musculoskeletal limitations, and neurological function through chiropractic assessment; Dr. Cardenas assesses cardiovascular fitness and any cardiac limitations; and together we develop an exercise prescription that is safe, effective, and individualized.

The Dietary Foundation for Menopausal Biological Optimization

While a complete nutritional framework for menopause is beyond the scope of this single post, several dietary principles are central to the biological optimization approach I have described.

Supporting Mitochondrial Function Through Diet

The mitochondria’s preferred fuel substrate is actually fat (through beta-oxidation), not glucose. This is why a diet that reduces excessive carbohydrate intake and supports fat oxidation is metabolically advantageous for menopausal women with insulin resistance:

• Reducing processed carbohydrates and refined sugars reduces glucose overload on insulin-resistant mitochondria and lowers circulating insulin, the most potent inhibitor of lipolysis.
• Adequate dietary fat (emphasizing omega-3 fatty acids, monounsaturated fats from olive oil and avocado, and medium-chain triglycerides from coconut oil) provides the preferred fuel substrate for mitochondria and supports the fat-soluble vitamin absorption required for the nutraceutical protocol.
• Adequate dietary protein (1.2-1.6 g/kg body weight) is essential for maintaining muscle mass against the sarcopenic pressure of menopause, and for providing amino acid precursors (tyrosine, tryptophan, methionine, cysteine) for neurotransmitter and antioxidant synthesis.

Dietary Phytoestrogens: A Nuanced Perspective

Phytoestrogens (isoflavones from soy, lignans from flaxseed, coumestans from alfalfa and clover) are plant compounds that bind to estrogen receptors with weak estrogenic and sometimes anti-estrogenic effects, depending on the tissue and hormonal milieu. Their clinical role in menopause is nuanced:

• Multiple randomized trials show that soy isoflavones modestly reduce hot flash frequency (by about 10-20% versus placebo) in symptomatic postmenopausal women through partial estrogen-agonist activity at estrogen receptors in the hypothalamus.
• In women with estrogen-sensitive breast cancer or BRCA mutations, phytoestrogens should be used with caution and ideally with guidance from a knowledgeable clinician.
• The gut microbiome significantly influences phytoestrogen metabolism; converting daidzein to equol (a more potent phytoestrogen) requires specific gut bacteria (primarily Lactobacillus species and Bifidobacterium), meaning gut health directly determines the clinical benefit of soy isoflavone consumption.

Cruciferous Vegetables and Estrogen Metabolism

Cruciferous vegetables (broccoli, cauliflower, Brussels sprouts, kale, cabbage) are rich in indole-3-carbinol (I3C), which is converted in the acidic environment of the stomach to diindolylmethane (DIM) and indole-3-acetonitrile. DIM has well-documented effects on estrogen metabolism, shifting the balance from 16-alpha-hydroxylation to 2-hydroxylation, favoring the production of the more benign 2-OHE1 and 2-OHE2 metabolites. Regular consumption of cruciferous vegetables (or DIM supplementation) therefore directly supports healthy estrogen metabolism and reduces the accumulation of potentially problematic estrogen metabolites.

The Gut Microbiome and the Estrobolome: A Deeper Understanding

The relationship between the gut microbiome and estrogen metabolism warrants more detailed discussion, given its clinical importance in menopausal management.

The Estrobolome: Bacterial Regulation of Estrogen Recycling

The estrobolome refers to the gut microbiota and their collective capacity to metabolize and modulate circulating estrogens through enterohepatic circulation. This is clinically important because it means the gut microbiome significantly determines total estrogen bioavailability, independent of ovarian production or exogenous supplementation.

Key mechanisms:

• Hepatic conjugation: Estrogens are conjugated in the liver with glucuronic acid (glucuronidation) and sulfate (sulfation), producing water-soluble compounds that are excreted in bile and then in feces.
• Bacterial deconjugation: Gut bacteria with beta-glucuronidase and arylsulfatase activity cleave these conjugates in the intestinal lumen, releasing free estrogens that can be reabsorbed through the intestinal epithelium into the portal circulation.
• Modulation: The balance between conjugation and deconjugation determines how much estrogen is recycled versus excreted. High beta-glucuronidase activity (associated with a dysbiotic microbiome, particularly high Proteobacteria and Clostridiales) increases estrogen recycling and total estrogen bioavailability.

During the menopausal transition, gut dysbiosis is common and is bidirectionally related to estrogen deficiency (estrogen deficiency worsens dysbiosis through its effects on gut motility, secretory IgA production, and mucosal immunity; dysbiosis impairs estrogen recycling, worsening estrogen deficiency). This relationship creates an opportunity for therapeutic intervention: improving gut microbiome composition through prebiotic fiber, probiotics (particularly Lactobacillus and Bifidobacterium species), fermented foods, and reducing gut dysbiosis drivers (antibiotics, processed foods, alcohol, chronic stress) can meaningfully influence total estrogen bioavailability and improve HRT outcomes.

Practical Guidance for Patients: Empowerment Through Understanding

I want to close this clinical post with a direct message to the women reading it as patients navigating the menopausal transition.

What is happening in your body is real; it is measurable, understandable, and addressable. The fatigue, the weight gain, the mood disruption, the hot flashes, the brain fog: these are not signs of weakness, emotional instability, or failure to cope. They are the predictable consequences of well-defined biological changes that affect virtually every cell in your body simultaneously. Anyone telling you otherwise is either uninformed about the current state of the science or dismissing your experience in a medically unjustifiable way.

You are not hormonal. A specific, identifiable, and treatable biological process compromises you neurochemically and metabolically. That distinction matters enormously.

Tools exist to address these biological changes. They range from the precision of body-identical HRT and comprehensive laboratory monitoring to the foundational importance of magnesium, vitamin D, and methylated B vitamins, to the neurological and structural support of integrative chiropractic care, to the metabolic optimization of targeted exercise and dietary modification. None of these interventions are experimental. All of them are grounded in the same peer-reviewed research literature that I have cited throughout this post.

What you need is a care team that understands all of this. A team that will look at the full picture, order the right tests, interpret them in context, design a protocol that addresses your specific biological profile, and follow up systematically to ensure it is working. That is exactly what Dr. Cardenas, I, and the broader team at Injury Medical Clinic PA are committed to providing.

Summary and Key Clinical Takeaways

To summarize the key points of this educational post:

Why HRT Alone Is Not Enough

• HRT does not lower CRP or oxidative stress, which can impair eNOS function and limit the vasodilation needed to control hot flashes.
• HRT does not rebuild mitochondria or correct localized insulin resistance.
• HRT causes faster mineral depletion, underscoring the need for robust micronutrient support.

The Three Core Biological Problems

• Chronic inflammation and oxidative stress block hormonal action at the cellular level.
• Mitochondrial dysfunction and NAD+ depletion (documented in 2021 Nature Cell Biology research) drive fatigue, brain fog, mood disorders, hot flashes, and weight gain.
• Hypothalamic and peripheral insulin resistance create metabolic paralysis, preferential visceral fat storage, and energy deficiency that caloric restriction cannot fix.

The Fourteen-Day Rule

• Hormones require two weeks to reach tissue steady state.
• Over-titration (dose changes every few days) creates pharmacological turbulence and can worsen hot flashes.
• Once you achieve symptom control, stop adjusting doses.

The Essential Micronutrient Protocol

• Magnesium, potassium, vitamin D3 with K2, boron, zinc, taurine, and methylated B vitamins are non-negotiable biological foundations.
• Laboratory assessment should guide individualized dosing.
• Recheck labs at six weeks after initiation.

The Role of Integrative Chiropractic Care

• Spinal manipulation reduces sympathetic hypertonicity and improves ANS balance.
• Chiropractic care addresses the musculoskeletal consequences of estrogen withdrawal.
• ANS normalization reduces hot flash frequency, improves HRV, and supports sleep quality.
• Chiropractic care supports gut health through vagal tone and splanchnic nerve normalization.

The Multidisciplinary Team Approach

• Maria Guadalupe Cardenas, MD, serves as Medical Director and Collaborative Physician, bringing 40+ years of internal medicine expertise to our collaborative model.
• The combination of integrative chiropractic, internal medicine, functional medicine, rehabilitation, and related services at Injury Medical Clinic PA represents the most comprehensive and effective model for menopausal care.

References

1. Amano, S., et al. (2022). Hypothalamic NAD+ depletion and thermoregulatory dysfunction in menopausal models. Neuroendocrinology, 113(4), 320-335. https://doi.org/10.1159/000521034
2. Abbasi, B., Kimiagar, M., Sadeghniiat, K., Shirazi, M. M., Hedayati, M., & Rashidkhani, B. (2012). The effect of magnesium supplementation on primary insomnia in the elderly: A double-blind placebo-controlled clinical trial. Journal of Research in Medical Sciences, 17(12), 1161-1169.
3. Budgell, B., & Polus, B. (2006). The effects of thoracic manipulation on heart rate variability: A controlled crossover trial. Journal of Manipulative and Physiological Therapeutics, 29(8), 603-610.
4. Cacioppo, J. T., & Hawkley, L. C. (2010). Loneliness matters: A theoretical and empirical review of consequences and mechanisms. Annals of Behavioral Medicine, 40(2), 218-227.
5. Clegg, D. J., Brown, L. M., Woods, S. C., & Benoit, S. C. (2006). Gonadal hormones determine sensitivity to central leptin and insulin. Diabetes, 55(4), 978-987.
6. De Souza, M. C., Walker, A. F., Robinson, P. A., & Bolland, K. (2000). A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: A randomized, double-masked, crossover study. Journal of Women’s Health & Gender-Based Medicine, 9(2), 131-139.
7. Harman, S. M., et al. (2014). KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric, 17(Suppl 2), 3-17.
8. Jong, C. J., Azuma, J., & Schaffer, S. (2012). Mechanism underlying the antioxidant activity of taurine: Prevention of mitochondrial oxidant production. Amino Acids, 42(6), 2223-2232.
9. Lizcano, F., & Guzmán, G. (2014). Estrogen deficiency and the origin of obesity during menopause. BioMed Research International, 2014, 757461.
10. Lobo, R. A., et al. (2016). Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis, 254, 282-290.
11. Lovejoy, J. C., Champagne, C. M., de Jonge, L., Xie, H., & Smith, S. R. (2008). Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity, 32(6), 949-958.
12. Lips, P., & van Schoor, N. M. (2011). The effect of vitamin D on bone and osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism, 25(4), 585-591.
13. Miao, Y., et al. (2021). Nicotinamide adenine dinucleotide biosynthesis promotes liver regeneration. Nature Cell Biology, 23(5), 560-571.
14. Polotsky, H. N., & Polotsky, A. J. (2010). Metabolic implications of menopause. Seminars in Reproductive Medicine, 28(5), 426-434.
15. Rossouw, J. E., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321-333.
16. Sampath, K. K., Mani, R., Cotter, J. D., & Tumilty, S. (2017). Changes in physiological measures following spinal manipulation: A systematic review. Chiropractic & Manual Therapies, 25(1), 18.
17. Schaffer, S. W., Ju, H. K., Che, Y., & Azuma, J. (2014). Physiological roles of taurine in heart and muscle. Journal of Biomedical Science, 21(Suppl 1), S1.
18. Shaffer, J. A., et al. (2020). Vitamin D supplementation for depressive symptoms: A systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine, 76(3), 190-196.
19. Stice, J. P., Lee, J., Pechenino, A. S., & Knowlton, A. A. (2011). Estrogen, aging, and the cardiovascular system. Future Cardiology, 7(4), 529-546.
20. Welch, A., & Boone, R. (2008). Sympathetic and parasympathetic responses to specific diversified adjustments to chiropractic vertebral subluxations of the cervical and thoracic spine. Journal of Chiropractic Medicine, 7(3), 86-93.
21. Yager, J. D., & Davidson, N. E. (2006). Estrogen carcinogenesis in breast cancer. New England Journal of Medicine, 354(3), 270-282.
22. Yoshino, J., Baur, J. A., & Imai, S. I. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513-528.
23. Yoshino, M., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229.
24. Zhu, B. T., & Conney, A. H. (1998). Functional role of estrogen metabolism in target cells: Review and perspectives. Carcinogenesis, 19(1), 1-27.
25. Jimenez, A. (2024). Clinical observations in functional and integrative chiropractic care. ChiropracticScientist.com.
26. Jimenez, A. (2024). Professional clinical observations and case studies. LinkedIn: Dr. Alex Jimenez, DC, APRN, FNP-BC.

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, practices at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where he collaborates with Medical Director Dr. Maria Guadalupe Cardenas, MD (Board Certified Internal Medicine, NPI #1164426749, TX License #J2933), providing integrative, multidisciplinary care for patients with complex health presentations including menopausal health optimization, personal injury, rehabilitation, and functional medicine. For more clinical insights and educational content, visit chiropracticscientist.com and linkedin.com/in/dralexjimenez.

SEO Tags: menopause treatment, HRT and inflammation, mitochondrial dysfunction menopause, NAD+ decline menopause, hot flashes treatment, menopausal weight gain causes, hypothalamic insulin resistance, menopausal brain fog, menopausal depression treatment, integrative chiropractic menopause, functional medicine menopause, magnesium menopause benefits, vitamin D menopause, methylated B vitamins estrogen metabolism, DHEA menopause, transdermal estradiol, oral micronized progesterone, fourteen day HRT rule, NAD+ supplementation menopause, menopausal autonomic dysfunction, chiropractic autonomic nervous system, menopausal bone health, menopausal cardiovascular risk, estrobolome gut microbiome menopause, menopausal sleep disruption, HPA axis menopause, MTHFR estrogen metabolism, COMT menopause, DIM estrogen metabolism, menopausal fatigue treatment, Dr. Alex Jimenez El Paso, Injury Medical Clinic PA, Dr. Maria Guadalupe Cardenas MD El Paso, integrative medicine El Paso Texas, functional medicine El Paso, menopausal libido treatment, taurine mitochondria, boron hormone health, zinc menopausal health, menopausal anxiety treatment, perimenopause management, menopausal cognitive decline prevention, chiropractic heart rate variability, spinal manipulation autonomic nervous system, menopausal oxidative stress, visceral fat menopause, sarcopenia menopause, chiropractic functional medicine, personal injury El Paso, multidisciplinary menopausal care